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Abstract
Accumulation of beta-amyloid (Aβ) in the brain is a major contributor to the
cellular pathology and cognitive impairment observed in Alzheimer’s disease
(AD). In part, Aβ exerts its toxic effects by increasing reactive oxygen species
(ROS) and neuroinflammation in the brain. Aging, a major risk factor for AD is
also associated with increased production of ROS. This study investigated the
age-related pathological response to Aβ toxicity and examined whether catalaseSKL (CAT-SKL), a genetically engineered derivative of the peroxisomal
antioxidant enzyme catalase, is able to reduce Aβ toxicity. Bilateral
intracerebroventricular (icv) injections of the Aβ25-35 peptide was used to model
Aβ toxicity in 3, 6 and 9 months old male Wistar rats. A subset of 6 months old
rats

undergoing

CAT-SKL

treatment

received

CAT-SKL

injections

intraperitoneally (ip) once a week for four consecutive weeks. Control animals
received bilateral icv injections of the reverse physiologically inactive Aβ35-25
peptide. Spatial learning and reference memory were assessed using the Morris
Water Maze (MWM); histopathological and immunohistochemical analyses were
used to evaluate neuroinflammation, and neuronal degeneration. Aβ25-35 icv
administration in animals 6 and 9 months of age resulted in increased microglia
activation and decreased number of cholinergic neurons in the basal forebrain
and loss of neuronal integrity in the hippocampus in comparison to Aβ25-35
induced pathology in 3 months old animals. CAT-SKL treatment significantly
decreased microglia activation and reduced cholinergic neuronal loss in the basal
forebrain. Aβ25-35 animals showed deficits in long-term reference memory in the
MWM, which was effectively ameliorated in Aβ25-35 animals treated with CATSKL. These findings demonstrate the importance of taking into consideration
animal age when modeling Aβ toxicity, and provides support for the use of CATSKL in reducing neuroinflammation and long-term reference memory deficits
induced by Aβ25-35 in the rat.
Key Words: Alzheimer’s disease, Aβ, Neuroinflammation, Oxidative Stress,
H2O2, Catalase
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Section 1
INTRODUCTION
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1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder and is the most
common cause of dementia in the elderly. Clinically, AD manifests itself in the
early stages as impairments in learning and memory. As the disease progresses
language, judgment, visuo-spatial skills and complex cognition are impaired,
compromising the ability of the affected individual to carry out the activities of
their day-to-day lives (Forstl and Kurz, 1999; Marcello 2008). AD is an agerelated disease with the prevalence rising with increasing age. At present, 5-8%
of Canadians over the age of 65 have AD, rising to approximately 30-50% of
Canadians over the age of 85 (Smetanin et al., 2009). In 2006, there were 26.6
million cases of AD worldwide, a number predicted to increase to 106.8 million by
2050, due to the aging world population (Brookmeyer, 2007). The number of
Canadians impacted by AD will continue to grow each year as the proportion of
the population over 65 increases. Therefore, the need to better understand the
pathophysiology of this age-related disease, and to find ways to delay the onset
and slow the progression of this disease is of utmost importance.
Alzheimer’s disease was first described by Alois Alzheimer in 1907 when
he presented the progressive symptoms and mental deterioration of his patient
Auguste D that left her delusional, aggressive and unable to remember recent
events. Following her demise, he noted overt neurofibrillary tangles and neuritic
plaques in her brain (Stelzmann et al., 1995). It wasn’t until 1984 however, that it
was discovered that beta-amyloid peptide (Aβ) was the primary protein
component of plaques (Glenner and Wong, 1984). Today, the histopathological
hallmarks of AD include the presence of extracellular amyloid plaques,
intracellular neurofibrillary tangles, inflammation, neuronal degeneration and loss,
and synaptic dysfunction and failure (Selkoe, 2001; Querfurth and LaFerla,
2010). Plaques are composed of insoluble extracellular aggregates of Aβ, a
sticky peptide generated from the proteolytic cleavage of amyloid precursor
protein (APP). Neurofibrillary tangles are the result of hyper-phosphorylation of
the microtubule stabilizing protein tau (Hardy and Selkoe, 2002).
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1.2 Genetics and Risk Factors
The cause of AD is thought to be due to complex interactions between
multiple genetic, and environmental factors. Autosomal dominant mutations in
the amyloid precursor protein (APP), presenilin-1 and presenilin-2 (PS1, PS2)
encoding genes have been identified and are known to cause early-onset (<60
years) familial AD. However, the majority of AD cases are classified as sporadic
and late-onset (>60 years) with the familial forms only accounting for 1-10% of
AD cases (Campion et al., 1999; Selkoe, 2001). Apart from the earlier age-of
onset for autosomal dominant forms of familial AD, both familial and sporadic AD
progress in highly similar manners, with the clinical manifestations and
pathophysiology of the disease processes usually being indistinguishable
between the two types (Selkoe, 2001).

Aside from the mutated genes

implicated in familial AD, the most important genetic risk factor for AD is
inheritance of the E4 allele of apolipoprotein E (apoE), the primary cholesterol
transporter in the brain. Inheritance of two apoE4 alleles significantly increases
the lifetime risk and lowers the age of onset of AD (Corder et al., 1993;
Morishima-Kawashima et al., 2000). The lifetime risk estimate of developing AD
for individuals with 2 copies of the apoE4 allele is around 60% by the age of 85,
in comparison to those individuals with 2 copies of the apoE3 allele whose risk of
developing AD by the age of 85 is around 10% (Genin et al., 2011).
Aging is the most important nongenetic risk factor for late-onset AD. Aging
is associated with oxidative stress, glial activation, increased production of
inflammatory mediators, decreased antioxidant functioning and accumulation of
modified proteins and lipids, all of which take a toll on the brain (Wyss-Coray and
Musck, 2002). However, despite all the changes that accompany the aging
process, aging alone is not sufficient to initiate the disease process, some
precipitating event is required. Risk factors that could be potential triggers for
late-onset AD include but are not limited to; traumatic brain injury, diabetes
mellitus, obesity, hyperlipidemia, hypertension, transient ischemic attacks, stroke
and atherosclerosis (Grammas, 2011; Herrup 2010). Of these many are vascular
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risk factors, suggesting that neurovascular dysfunction may contribute to the
onset and/or progression of neurodegenerative events in AD (Grammas, 2002;
2011).
1.3 Vulnerable brain regions in Alzheimer’s disease
AD causes a large loss in brain weight and volume, with vulnerable
neuronal populations and brain areas being affected more than others (Huang
and Mucke, 2012). Specifically, AD causes neuronal degeneration and loss in
regions of the brain important for memory and learning with areas including the
hippocampus, frontal cortex and limbic areas being particularly vulnerable
(Marcello et al., 2008; Venkateshappa et al., 2012). Neuronal loss in these
regions leads to significant impairments in intellectual abilities that are severe
enough to disrupt social and occupational functioning (Gotz et al., 2011). One of
the first neuronal populations identified as being vulnerable in AD was neurons
synthesizing and releasing acetylcholine. Changes in activity of synthetic choline
acetyltransferase and degradative acetylcholinesterase in the limbic and cerebral
cortices along with loss of cholinergic cell bodies in the subcortical nuclei that
project to these regions has been demonstrated in both human AD brains and in
animal models of the disease (Selkoe, 2001). Specifically, degeneration of
cholinergic neurons in the basal forebrain, which provides major cholinergic
inputs to the hippocampus and neocortex, is thought to be one of the first
neuronal populations affected in the disease process (Whitehouse et al., 1982;
Coyle et al., 1983; Pearson et al., 1983; Schliebs, 2005). The basal forebrain
cholinergic system is comprised of cell bodies in the medial septal nucleus
(MSN), the vertical and horizontal bands of Broca (VDB, HDB) and the nucleus
basalis of Meynert (NM) (Reviewed by Collerton, 1986; D’Hooge and De Deyn,
2001; Auld et al., 2002). Clinically, basal forebrain cholinergic deficits positively
correlate with cognitive impairments and behavioral disturbances in human
patients with dementia (Perry et al., 1978; Collerton, 1986; Minger et al., 2000).
Cholinergic deficit has been reported as a result of Aβ administration,
suggesting Aβ may contribute to cholinergic dysfunction. Both single injections
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and chronic intracerebroventricular infusion of Aβ have been shown to induce
degeneration of cholinergic neurons in the basal forebrain and cause memory
impairment in rats (Vaucher et al., 2001; Stepanichev et al., 2004). In addition to
significant neuronal loss, studies have demonstrated decreases in choline
acetyltransferase activity and acetylcholine release in the basal forebrain in
response to Aβ administration; implicating Aβ as a contributor to basal forebrain
cholinergic system neuropathology (Auld et al., 2002). The severe cholinergic
degeneration observed in AD patients lead to the development of drugs focusing
on enhancing acetylcholine levels. Currently, the only drugs approved to date for
treatment of AD in the United States target this neuronal population (Selkoe,
2001; Auld et al., 2002; Donev et al., 2009).
The hippocampus, a region of the brain that plays a key role in cognitive
functioning, is one of the brain regions most vulnerable to the aging process, and
demonstrates substantial AD pathology. Both in humans and in animal models of
AD, the severity of cognitive decline is positively correlated with the extent of
structural and functional modifications occurring in the hippocampus (Gallagher
and Nicolle, 1993; Landfield, 1988; Hayakawa et al., 2007). In the human AD
brain, substantial neuronal loss occurs in the hippocampus, particularly in the
CA1 region (West et al., 1993; 2004). However, preclinical AD brains are not
associated with significant neuronal loss in the CA1 or any other subdivisions of
the hippocampus. Thus, while the hippocampus is one of the first regions of the
brain to demonstrate AD pathology, including Aβ deposition and tau pathology,
neuronal loss in the hippocampus only occurs later in the disease process. Mice
genetically altered to express the genes associated with familial AD (APP, PS1,
PS2), show inflammation and substantial amyloid deposition in the hippocampus,
most notably in the CA1, and CA3 hippocampal regions. However, despite the
pathology and cognitive decline shown in transgenic mouse models of AD they
demonstrate correspondingly little neurodegeneration (Abramowski et al., 2012),
suggesting they are models of the earlier, preclinical stages of AD.
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1.4 Beta amyloid
Aβ is a peptide of 37-43 amino acids that is generated by proteolytic cleavage
of the amyloid precursor protein (APP) by the action of β-and γ-secretases (Shoji
et al., 1992; Haass and Selkoe, 1993). The physiological role of APP, a
transmembrane protein, remains poorly understood, however it is thought to be
involved in cell-cell interactions and cell-substrate adhesions (Reviewed by
Nalivaeva and Turner, 2013). APP is highly conserved in evolution and
expressed in all mammals in which it has been sought (Selkoe 2001; Jacobsen
et al., 2009). Production of Aβ is a normal cellular event, and can be detected in
both the cerebrospinal fluid and plasma of healthy humans throughout life
(Seubert et al., 1992; Shoji et al., 1992). Recent studies have demonstrated that
at normal physiological concentrations Aβ oligomers can positively regulate
learning and memory (Lublin and Gandy, 2010).

However, altered protein-

processing resulting in abnormal Aβ accumulation has inextricably been tied to
the neuropathology of AD. This accumulation can be caused by overproduction
of Aβ as seen in the familial forms of the disease (Citron et al., 1992; Cai et al.,
1993; Bentahir et al., 2006), or due to the inability to properly clear Aβ (Hardy
and Selkoe, 2002; Mawuenyega et al., 2010). Aβ is produced when β-secretase
cleaves APP to generate a soluble version of APP (sAPPβ) and a 99-amino acid
carboxy-terminal fragment that remains membrane bound (Seubert et al., 1993).
The carboxy-terminal fragment can then be subsequently cleaved in the middle
of the transmembrane domain by γ-secretase to produce Aβ (Haass et al., 1992;
Haass and Selkoe 1993). The cleavage by γ-secretase at the carboxy-terminus is
heterogeneous and dictates the length of the Aβ peptide produced. Following the
non-amyloidogenic pathway APP is cleaved within the Aβ domain by αsecretase, which precludes Aβ generation (Esch et al., 1990; Sisodia 1992;
Eckman and Eckman, 2007). β-Secretase activity has been attributed to one
protease, namely beta-site APP-cleaving enzyme 1 (BACE1) (Cai et al., 2001)
whereas a set of four proteins is required to form the γ-secretase complex.
Presenilin along with the additional cofactors nicastrin, anterior-pharynx-defective
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phenotype (APH-1) and PS-enhancer (PEN-2) together form the proteolytic γsecretase complex (De Strooper, 2003).
Aβ has the ability to spontaneously aggregate into multiple coexisting
physical forms. Among these are Aβ oligomers (2-6 peptides) which can fuse to
form intermediate amyloid assemblies. Aβ can also form fibrils, which make up
the β-pleated sheets that go on to become insoluble fibers of advanced amyloid
plaques (Querfurth and LaFerla, 2010). Soluble Aβ oligomers identified in the
brains of AD patients include Aβ1-40 and Aβ1-42. Of the Aβ species, Aβ1-40 is more
abundantly produced, however Aβ1-42 is considered the more toxic species as it
is particularly prone to aggregation, and thus much more likely to form oligomers
(Selkoe 2001; Walsh and Selkoe 2007; Querfurth and Laferla, 2010). Enzymatic
cleavage of Aβ1-40 by brain proteases can also produce the truncated Aβ
fragments Aβ25-35 and Aβ25-40 (Kaneko et al., 2001). Aβ25-35 is the shortest Aβ
peptide sequence that can form β-sheet aggregated structures and retains
biological activity comparable to full length Aβ (Yankner et al., 1989; Pike et al.,
1995; Millucci et al., 2009). These truncated Aβ25-35 fragments are present in
the brains of AD patients, but not in age-matched controls (Kubo et al., 2002).
The Aβ25-35 fragment is a useful tool for studying Aβ toxicity as it induces similar
toxicity to that of the full length Aβ fragments, while its shorter length allows for
better solubility and rapid aggregation into soluble oligomers (Kowall et al., 1992;
Millucci et al., 2009).
1.5 The Amyloid Cascade hypothesis
According

to

the

amyloid

cascade

hypothesis

the

progressive

accumulation and deposition of neurotoxic Aβ in amyloid plaques in the brain is
thought to be an initiating factor in the pathogenesis of AD

(Hardy and Allsop,

1991; Hardy and Higging, 1992; Hardy and Selkoe 2002). There are several
major pieces of evidence implicating Aβ as playing a causative role in AD. One of
the first was localization of the APP gene to chromosome 21. Those individuals
with Down syndrome (trisomy of chromosome 21) demonstrate a neuropathology
essentially identical to that seen in AD as a result of increased APP expression
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and consequently higher Aβ levels (Eckman and Eckman, 2007, Walsh and
Selkoe, 2007). In the brains of Down syndrome patients the accumulation of Aβ
precedes tau pathology and neuronal loss. The brains of AD patients also
consistently show higher levels of both soluble and insoluble Aβ1-40 and Aβ1-42 in
comparison to the normally aged brain, with Aβ deposition preceding tau
pathology and neurodegenerative changes (Morishima-Kawashima et al., 2000;
Eckman and Eckman, 2010). This provides convincing evidence in support of the
involvement of Aβ in AD, and further suggests that Aβ is one of the initiating
factors in the pathogenesis of AD.
Additionally, the genes identified as playing a role in familial forms of AD,
including the APP and presenilin genes, all increase the production and
accumulation of Aβ. Numerous studies have since demonstrated that mice
genetically engineered to overexpress human APP show a time-dependent
increase

in

extracellular

Aβ

and

demonstrate

cognitive

decline

and

neuropathological changes that mimic what is seen in human AD patients
(Yamada and Nabeshima, 2000; Gotz et al., 2004). Aβ peptides have also been
shown to be toxic to hippocampal and cortical neurons both in culture and in vivo
(Pike et al. 1991; Lambert et al. 1998; Hoshi et al., 2003; Deshpande et al. 2006).
The precise molecular mechanisms by which Aβ exerts its toxicity is still unclear
however, the addition of toxic forms of Aβ in neuronal culture results in
membrane damage, calcium ion influx, oxidative free radical production and
damage, inflammation and apoptosis (Tabner et al., 2005; Deshpande et al.
2006).
Despite the evidence for the contribution of Aβ to AD pathology, accumulation
of Aβ has also been reported in the brains of the elderly whose cognitive
functioning is still intact (Dickson et al., 1992; Aizenstein et al., 2008). Moreover,
amyloid plaque load determined histopathologically and radiologically, does not
correlate well with severity of dementia (Walsh and Selkoe, 2007; Huang and
Mucke 2012). This lack of correlation between plaque load and cognitive
impairment was further substantiated by studies in APP transgenic mice where
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memory impairment and changes in neuron function are observed well before the
first signs of amyloid plaque deposition (Walsh and Selkoe, 2007). This lead to
a conundrum regarding the exact role of Aβ in the disease process, as Aβ plaque
burden was not coinciding with cognitive deficits yet Aβ was inextricably tied to
the disease process. In 1995, a study by Oda et al., suggested that soluble
complexes of Aβ, rather than Aβ fibrils were the toxic Aβ species. Further support
for the idea that soluble Aβ oligomers had neurotoxic properties came in 1998,
when a group demonstrated that Aβ oligomers rapidly inhibit long-term
potentiation, an experimental paradigm representative of memory and synaptic
plasticity (Oda et al., 1995; Lambert et al., 1998; Marcello et al., 2008). Their
work and the subsequent studies of others lead to an update on the amyloid
cascade hypothesis that suggested early Aβ protein assemblies of various types,
including protofibrils, soluble oligomers and Aβ derived diffusible ligands may be
the true neurotoxic forms of Aβ (Tabner et al., 2005; Krafft and Klein, 2010).
This has since been supported by the finding that compared to the normally aged
brain, the AD brain has higher levels of soluble Aβ and moreover, the extent of
synaptic loss and severity of cognitive decline correlates with the amount of
soluble Aβ in the brain (Eckman and Eckman, 2007; Zussy et al., 2013).
1.6 Cerebral amyloid angiopathy and vascular dysfunction in AD
Epidemiological, clinical, pathological and neuroimaging studies have
implicated neurovascular dysfunction as playing a role in the pathogenesis of AD
(Dickstein et al., 2010). Studies in humans and animal models of AD suggest that
cerebrovascular dysfunction may precede cognitive decline and the onset of
neurodegenerative changes and exacerbate underlying AD pathology (Bell and
Zlokovic, 2009; Merlini et al., 2011; Murray et al., 2011). In particular, elevated
levels of Aβ have been closely linked to vascular changes, and implicated in the
vascular pathology of AD. Aβ plaques accumulate on and around cerebral
capillaries (Bell and Zlokovik, 2010) and 70-90% of AD patients show amyloid
deposition in the small arterioles, venules and capillaries within the cerebral
cortex (Selkoe, 2001; Humpel, 2011).
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Amyloid deposition in and along the walls of the cerebral blood vessels
leads to a condition called cerebral amyloid angiopathy (CAA). CAA has been
linked to cognitive impairment, and the incidence of CAA increases with age, with
10-40% of the elderly population without AD showing amyloid deposition in the
microvessels of the brain (Bell and Zlokovic, 2009). CAA can lead to narrowing
of the blood vessels resulting in hypoperfusion, capillary abnormalities, disruption
and breakdown of the blood-brain barrier and micro-aneursyms (Dickstein et al.,
2010; Querfurth and LaFerla, 2010; Humpel, 2011). CAA has also been shown to
be a significant cause of cerebral hemorrhage in the elderly population (Bell and
Zlokovic, 2009). Mouse models of AD harboring APP mutations also demonstrate
CAA, with Aβ deposits in the neocortical, hippocampal and thalamic vessel walls
(Calhoun et al., 1999; Miao et al., 2005).
1.7 Neuroinflammation
Aβ deposition and intracellular tau accumulation are capable of triggering
pathological cascades in the brain that set it down a destructive path to cell death
and a diseased state. Such is the case with the brain’s dysregulated
inflammatory and oxidative response to Aβ toxicity. It has been well established
that neuroinflammation is involved in the pathogenesis of AD (Akiyama et al.,
2000; Wyss-Coray and Mucke, 2002; Tuppo and Arias, 2005). In the AD brain,
up-regulated inflammatory mechanisms are co-localized with those regions of the
brain exhibiting high levels of AD pathology. Moreover, in regions of the brain
showing low levels of AD pathology, inflammatory mediators are absent or
minimal (Lue et al., 1996). Common neuroinflammatory events include; upregulation of inflammatory cytokines and chemokines, activation of the
complement system, release of reactive oxygen species (ROS) and activation
and proliferation of microglia and astrocytes (Akiyama et al., 2000). Aβ is thought
to be one of the key contributors to the chronic inflammatory response in the AD
brain. Evidence for this comes from analysis of human AD brains where
inflammatory mediators are most highly expressed in the vicinity of Aβ deposits
and from studies that have demonstrated Aβ aggregates activate a variety of
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inflammatory pathways, including Aβ-mediated activation of microglia and
astrocytes as well as the complement pathway (Akiyama et al., 2000; Bamberger
and Landreth, 2002; Wyss-Coray and Mucke, 2002). At what point inflammation
arises in the course of AD had not yet been fully resolved. However, Aβ and
inflammation appear to work in a self-propagating cycle, with inflammation
stimulating the production of Aβ, and Aβ activating and promoting the release of
inflammatory mediators (Grammas, 2011).
Microglia and astrocytes are the cell mediators of inflammation in the brain.
Changes in microglia morphology from a ramified (resting) state to that of the
amoeboid (active) state, along with astrocytosis, involving increases in number
and size of astrocytes have been demonstrated in AD (Glass et al., 2010).
Astrocytes are the most common cells in the brain and perform many essential
functions under normal physiological conditions including maintaining the
functional connectivity of neuronal synapses, regulating the activity of neurons
and providing nutrients to the nervous tissue. The precise role of astrocytes in
the inflammatory process is not fully understood, however, they have been
shown to secrete pro-inflammatory products in response to Aβ toxicity, and
accumulate around Aβ deposits in the brain. Microglia are the ‘macrophages’ of
the brain, serving as the immunocompetent defense cells orchestrating the
central nervous system (CNS) immune response. Activated microglia surround
and invade Aβ plaques in both the human AD brain and in APP transgenic mice
that develop Aβ plaques (Reviewed by Akiyama et al, 2000; Herrup, 2010).
Initially, this neuroinflammatory response is involved in the clearance of Aβ from
the brain, with the phagocytic microglia actively engulfing and degrading Aβ.
However, after prolonged activation microglia have been shown to release a
variety of pro-inflammatory mediators, and potentially neurotoxic substances.
These include secretion of the cytokines interleukin-1, interleukin-6 and tumor
necrosis factor α, secretion of the chemokines interleukin-8, and macrophage
inflammatory protein-1 α along with cell surface expression of MHC class II, and
activation of the complement pathway (Akiyama et al, 2000; Tuppo and Arias,
2005; Dumont and Beal 2010; Querfurth and LaFerla, 2010). Inflammatory cells
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also have the potential to produce large amounts of ROS, including superoxide
radicals and hydrogen peroxide (H2O2). An increased level of ROS leads to
oxidative stress, further exacerbating the neuroinflammatory process (Akiyama et
al., 2000; Massaad 2011).
The substantial evidence implicating inflammation in the pathogenesis of
AD lead to the idea that therapeutic strategies targeting inflammation would be
beneficial in slowing the onset and progression of AD. In support of this,
retrospective studies demonstrated that nonsteroidal anti-inflammatory drugs
(NSAIDs) lower the lifetime risk of AD by 30-60% and further slow the
progression of the disease (Herrup, 2010; Querfurth and Laferla, 2010). While
these results were initially encouraging, numerous randomized clinical trials of
NSAIDs have failed to show any evidence for the reduction of AD pathology or
the slowing of cognitive decline (Herrup, 2010; Querfurth and LaFerla, 2010). In
part, this failure of prospective human trials of NSAIDs could be attributed to the
fact that these trials were only begun after the disease had already progressed
and AD symptoms were already manifest (Herrup, 2010). Instead targeting
inflammatory pathways at the initial or preclinical stages of the disease might be
more effective, as this would aid in preventing or slowing the progression of the
disease, rather than attempting to reverse existing pathology.
1.8 A role for peroxisomes and mitochondrial dysfunction in Alzheimer’s
disease
Closely related to inflammation in the brain, is the role of ROS. There is
mounting evidence that oxidative stress resulting from free radical damage plays
a role in the pathology of AD and other neurodegenerative diseases. When
considering the role of oxidative stress in AD, one has to examine the organelles
primarily

responsible

for

the

production

and

elimination

of

ROS—the

mitochondria and peroxisomes. Mitochondria are considered the powerhouses of
the cell due to their role in adenosine triphosphate (ATP) production however
they are also involved in many other cellular functions including calcium
regulation, alteration of reduction-oxidation potential of cells, free radical
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scavenging, and apoptosis. During the process of ATP production, a subset of
electrons transferred through the respiratory chain form ROS. Under normal
physiological conditions these ROS are kept in check by the endogenous
antioxidant enzymes including superoxide dismutase, catalase, glutathione
reductase, and glutathione peroxidase. However, with aging mitochondrial
changes occur, resulting in a decline in electron transport chain function and an
increase in free radical production. Aβ has also been shown to interact with
mitochondria, inhibiting key mitochondrial enzymes, having detrimental effects on
mitochondrial functioning. Aβ associated mitochondrial dysfunction has been
reported in AD postmortem brains, in transgenic mouse models of AD and in
cellular Aβ toxicity work. Consequently, dysfunctional mitochondria release free
radicals, which in both the aging and AD brain cause substantial oxidative stress
(Pagani and Eckert, 2010; Swerdlow, 2011; Leuner et al., 2012; Mao et al.,
2012).
Peroxisomes are subcellular organelles present in almost all eukaryotic
cells, including neurons and glial cells in the brain. They perform a variety of
anabolic and catabolic functions including the β-oxidation of very long chain fatty
acids, biosynthesis of plasmalogens, and the metabolism of saturated and
polyunsaturated fatty acids. Additionally, they play a role in both the production
and removal of ROS in the cell under both physiological and pathological
conditions. A decline in peroxisomal function has been associated with cellular
aging and in age related neurodegenerative diseases, with a resultant increase in
oxidative stress and neuroinflammation as a consequence (Lizard et al., 2011;
Titorenko and Terlecky, 2011). Evidence for peroxisomal dysfunction in AD
comes from in vitro and in vivo work. In vitro, Aβ toxicity was shown to result in a
loss of peroxisomes in primary rat hippocampal neurons. Moreover, treatment
of Aβ challenged hippocampal neurons with a peroxisomal proliferator was
shown to protect them from Aβ toxicity by reducing neuronal death, indicating
that proper peroxisomal functioning may be neuroprotective (Santos et al., 2005).
In a transgenic mouse model of AD significant peroxisomal alterations were
observed in rats 3 months of age, when no apparent neuroanatomical or
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cytological signs of the disease were present, suggesting peroxisomal
dysfunction may be one of the earlier contributors to the disease process (Cimini
et al., 2009). Peroxisome-related dysfunction has also been reported in the
postmortem brain tissue of patients with AD (Kou et al., 2011). The exact
contribution that mitochondrial and peroxisomal dysfunction plays in aging and
AD is yet to be elucidated, however it is clear that impairment in these organelles
leads to increased levels of free radicals and resultant oxidative stress.
1.9 Reactive Oxygen Species and Oxidative Stress
Oxidative stress occurs when free radical production exceeds antioxidant
defense mechanisms leading to oxidative damage of various cellular components
including oxidation of lipids, proteins, and nucleic acids. The brain consumes
approximately 20% of the body’s total oxygen due to its high metabolic demand
and need for ATP. This disproportionately high level of oxygen consumption
combined with the brains abundant lipid content and relative scarcity of
antioxidant enzymes compared with other organs leaves the brain particularly
susceptible to increased production of ROS and oxidative stress (Markesbery
and Carney 1999, Su et al., 2008; Massaad 2011). The aging process is also
associated with high levels of ROS, along with a reduction in the ability to defend
against oxidative stress (Su et al., 2008; Massaad, 2011).
Regions of the aging brain that have been shown to be particularly
susceptible to neurodegeneration demonstrate increased oxidative damage and
lowered antioxidant functioning. A study by Venkateshappa et al., showed
increased levels of protein oxidation and protein nitration in the hippocampus and
frontal cortex compared to the cerebellum with increasing age in the human
brain. Moreover, these changes were associated with a decrease in activity of
the antioxidant enzymes superoxide dismutase and catalase (Venkateshappa et
al., 2012). Age-related alterations in antioxidant enzyme activities have also been
demonstrated in rats; with decreases in superoxide dismutase and catalase
activities being noted in the cerebral cortex of aging animals (Alper et al., 1998).
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Reactive oxygen species are generated in a number of cellular locations,
including the aforementioned organelles—peroxisomes and mitochondria. They
are produced as a normal consequence of cellular activity, as is the case during
aerobic metabolism where ROS are produced in the reduction of molecular
oxygen to water and in peroxisomes during β-oxidations of fatty acids
(Markesbury & Carney, 1999; Mohsenzadegan & Mirshafiey, 2011; Terlecky et
al., 2012). A number of ROS exist including the superoxide anion (O2), hydrogen
peroxide (H2O2), singlet oxygen and the hydroxyl radical (OH) (Markesbury &
Carney, 1999; Schrader and Fahimi, 2006). Typically ROS are categorized as
neurotoxic molecules, exerting their detrimental effects via oxidation of essential
molecules. However, ROS are also necessary for normal cellular functioning and
have been shown to play important roles in signaling, synaptic plasticity, and in
the immune system where they contribute to an organism’s defense against
microbial agents (Massaad 2011; Mohsenzadegan & Mirshafiey, 2011).
ROS are usually maintained at low physiological levels by antioxidants
and antioxidant enzymes. Some of the enzymatic antioxidants synthesized by
cells

include

superoxide

dismutase,

glutathione

peroxidase,

glutathione

reductase and catalase (Markesbury and Carney, 1999; Su et al., 2008).
Reduction of molecular oxygen yields the superoxide anion, which is converted
to H2O2 by superoxide dismutase. Hydrogen peroxide can then either be reduced
to form the highly reactive hydroxyl radical, or can be broken down by catalase or
glutathione peroxidase (Markesbery and Carney, 1999). In addition a number of
nonenzymatic antioxidants exist including α-tocopherol (vitamin E), ascorbic acid
(vitamin C), glutathione, and carotenoids, all of which assist in maintaining ROS
levels. These antioxidants are able to remove and or repair molecules that are
oxidized, defending cells against free radical damage.

However, when ROS

levels exceed the antioxidant capabilities of the cell, oxidative damage results.
The brains high demand for oxygen, coupled with increased levels of ROS
accompanying the aging process, set the aging brain up to be particularly
vulnerable to oxidative stress. Thus, it comes as no surprise that oxidative stress
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contributes to the pathophysiology of AD, an age-related neurodegenerative
disease. In fact, evidence indicates that one of the earliest pathological events in
AD is oxidative damage to the brain (Tabner et al., 2005). In transgenic mouse
models of AD, markers of lipid and protein oxidation are increased prior to
amyloid deposition (Resende et al., 2008). The early involvement of oxidative
stress in AD is further supported by evidence in Down’s syndrome patients where
oxidative damage has been shown to precede Aβ build up (Nunomura et al.,
2000; Milton 2001).
Numerous studies have demonstrated oxidative damage in the brains of
AD patients, including increased products of lipid peroxidation, protein oxidation
and oxidative damage to nucleic acids (Markesbury and Carney, 1999). Two of
the major products of lipid peroxidation in the AD brain are 4-hydroxy-2transnonenal (HNE) and acrolein, both of which are α, β-unsaturated aldehydes,
capable of binding to brain proteins and significantly altering their structure and
function (Butterfield et al., 2001). HNE has been shown to be elevated in multiple
brain regions and in ventricular cerebrospinal fluid in AD patients compared to
age matched controls (Sayre et al., 1997; Markesbery and Lovell 1998).
Additionally, HNE levels are increased in rat hippocampal neurons in response to
Aβ toxicity (Mark et al., 1997), and HNE has been shown to damage cholinergic
neurons and inhibit choline acetyltransferase activity in the basal forebrain
(Bruce-Keller et al., 1998). Acrolein is also reported to be increased in the brain
in AD compared to age matched controls, and has been shown to be toxic to
primary hippocampal cultures (Lovell and Markesbery, 2001). The most
commonly oxidized DNA base product as a result of ROS attack is 8-hydroxy-2’deoxyguanosine (8-OHdG). 8-OHdG levels are elevated in the AD brain and in
the cerebral spinal fluid of AD subjects (Lovell and Markesbery, 2001). Moreover,
immunohistochemical

detection

has

revealed

that

8-OHdG

and

8-

hydroxyguanosine (8-OHG) markers of oxidatively damage DNA and RNA
respectively, are restricted to hippocampal and neocortical neurons in the AD
brain, the same neurons known to be vulnerable and to degenerate in AD
(Nunomura et al., 1999; Markesbery and Carney, 1999).
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1.10 Beta-amyloid and H2O2
Of particular relevance to oxidative stress and AD is the contribution of the Aβ
peptide to the generation of ROS (Figure 1). Numerous studies have
demonstrated the ability of Aβ to generate hydrogen peroxide (H2O2) in neuronal
cell cultures (Behl et al., 1994; Goodman et al., 1994; Manelli and Puttfarcken,
1995). The production of H2O2 has been shown to occur early in the Aβ
aggregation process, when oligomers and protofibrils are formed, while mature
Aβ fibrils lack the ability to generate H2O2 (Tabner et al., 2005). Included among
the amyloidogenic proteins and peptides shown to have the ability to generate
H2O2 are Aβ1-40, Aβ1-42 and Aβ25-35 while controls, including scrambled and
reverse peptides were shown to lack any significant H2O2 producing ability when
tested under the same experimental conditions (Tabner et al., 2005). Hydrogen
peroxide is a stable, uncharged and freely diffusible ROS that is an effective
oxidant for many biological molecules. Its stability and diffusion properties allow
H2O2 to move within and between cells with relative ease, enhancing its toxicity
(Milton, 2004). Hydrogen peroxide is readily converted into the highly reactive
hydroxyl radical in the presence of iron (Fe2+) or copper (Cu+) (Milton, 2004;
Tabner et al., 2005). The reaction of iron with H2O2 to produce the hydroxyl
radical is termed the Fenton reaction (Markesbury and Carney, 1999).

The

hydroxyl radical in turn is then capable of damaging carbohydrates, DNA, protein
and lipids (Milton, 2004).
The mechanism for the generation or rise in H2O2 levels associated with Aβ
toxicity remains unclear. However, it may involve direct formation of ROS by Aβ
with the involvement of metal complexes, via activation of the enzymes that can
directly or indirectly generate ROS, or as a result of reduced degradation of H202
in Aβ challenged cells (Milton, 2001; 2004; Habib 2010). Nonetheless, the ability
of Aβ to increase H2O2 accumulation in cells suggests that H2O2 or one of its
metabolites plays a role in the cytotoxicity of Aβ (Behl et al., 1994; Milton, 2004;
Varadarajan et al., 2000).
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Figure 1. Role of Aβ in the production of reactive oxygen species (ROS)
and the resultant oxidative stress in Alzheimer’s disease. Genetic factors
including amyloid precursor protein (APP) or presenilin mutations and presence
of apolipoprotein E4 (apoE4) allele or other stressors including vascular risk
factors (hypertension, transient ischemic attacks, stroke, atherosclerosis)
contribute to Aβ accumulation in the brain. Aβ toxicity results in increased free
radical production (particularly H2O2), is associated with mitochondrial and
peroxisomal dysfunction and activates inflammatory cells, which in turn release
ROS. An increased level of ROS leads to oxidative damage of lipids, proteins
and DNA/RNA. Aging also contributes to oxidative stress and has been shown to
result in mitochondrial and peroxisomal dysfunction along with increased
production of inflammatory mediators and ROS.
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The peroxidase enzymes, which remove H2O2, include glutathione peroxidase,
thioredoxin dependent peroxidases and catalase, all of which are present in the
brain (Milton, 2004). Of these enzymes degradation of H2O2 is primarily achieved
by catalase in the peroxisomes and glutathione peroxidase, a cytosolic enzyme
(Schrader and Fahimi, 2006). In considering the role of oxidative stress in the
pathophysiology of AD, the balance between the generation and removal of ROS
by antioxidant enzymes is of utmost importance. Modification of the activities of
these antioxidant enzymes could be potential pharmacological targets for future
AD therapy (modified Milton, 2004).
1.11 Catalase-SKL: a targeted antioxidant approach
Catalase is heme containing tetrameric enzyme, predominantly found in
peroxisomes, that catalyzes the conversion of H2O2 to water and oxygen.
Deficiencies in catalase activity, expression and peroxisomal localization are
associated with oxidative stress, aging and human disease (Sheikh et al., 1998;
Wood et al., 2006; Terlecky et al., 2006; Koepke et al., 2007). Catalase is
targeted to peroxisomes by a type 1 peroxisomal targeting signal (PTS1), with
the carboxy-terminus residues, lysine-alanine-asparagine-leucine (KANL). This
targeting sequence is different from the classical PTS1 of other peroxisomal
enzymes, which have a serine-lysine-leucine (SKL) consensus sequence (Sheikh
et al., 1998; Koepke et al., 2007). The PTS1 KANL only poorly targets catalase to
peroxisomes, and as cells age it has been shown that catalase is increasingly
mislocalized to the cytosol (Koepke et al., 2007). The poor targeting efficiency of
the KANL sequence coupled with the mislocalization of catalase to peroxisomes
as cells age is associated with accumulation of H2O2 in cells and resultant
oxidative injury. In order to better target catalase to peroxisomes, a genetically
engineered variant of the enzyme, catalase-SKL (CAT-SKL), has been
developed (United States patent 7601366). This recombinant enzyme is able to
enter cells and traffic to organelles (mostly peroxisomes) where it is able to
efficiently metabolize H2O2 (Koepke et al., 2007; Young et al., 2007; Price et al.,
2009; Undyala et al., 2011). Use of CAT-SKL has been shown to restore
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catalase levels and oxidative equilibrium in hypocatalesemic fibroblasts (Wood et
al., 2006), delay the appearance of aging markers in human fibroblasts (Koepke
et al., 2007), reduce tumor necrosis factor α (TNF-α) induced production of
inflammatory cytokines in primary human keratinocytes (model of inflammatory
skin disease) (Young et al., 2008) and protect cardiac myocytes from hypoxiareoxygenation and ischemia reperfusion injury (Undyala et al., 2011).
The anti-inflammatory and anti-oxidant properties of CAT-SKL demonstrated
in vitro, make it a viable candidate for targeting oxidative stress and inflammation
in vivo. The use of CAT-SKL may therefore be beneficial in reducing Aβ toxicity
since Aβ mediates its toxicity in part by increasing H2O2 levels and triggering
neuroinflammatory cascades. The use of catalase to protect cells from Aβ toxicity
has already been demonstrated in cell cultures, with the addition of catalase to
the extracellular environment or transfection of cells with catalase decreasing the
toxicity induced by Aβ (Behl et al., 1994; Goodman et al., 1994; Manelli and
Puttfracken, 1995; Zhang et al., 1996). This protection was attributed to
decreases in H2O2 levels both inside and outside the cell (Habib et al., 2010).
Furthermore, inhibition of cellular catalase enhances Aβ1-42 and Aβ25-35 toxicity in
both neuronal and non-neuronal cell lines (Milton, 2001).
In cell cultures, Aβ1-42 and Aβ25-35 have been shown to bind with high affinity to
catalase both in peroxisomes and in the cytosol. Specifically, catalase is able to
directly bind the cytotoxic region of Aβ. This Aβ-catalase binding results in
significant inhibition of H2O2 breakdown by catalase, leading to ROS
accumulation and toxicity in cells (Milton, 1999; Milton, 2001; Habib et al., 2010).
Catalase-amyloid interaction also appears to occur in the brains of AD patients,
where catalase is associated with senile plaques (Pappolla et al., 1992; Lovell et
al., 1995). Thus, increasing catalase levels in the brain may aide in reducing the
toxicity induced by the Aβ peptide, with lowered ROS production, decreased
neuroinflammation and reduced neuronal dysfunction as a result.
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1.12 Modeling AD in animals
The complex pathophysiology of AD makes modeling the disease in
animals a challenge. Nonetheless, a number of transgenic and non-transgenic
animal models of AD exist, each with their own strengths and limitations. While
these animal models are incapable of simulating all aspects of the disease
process, they are of value in aiding our understanding of aspects of the disease.
Rodents genetically engineered to overexpress genes associated with AD
including APP, PS1/PS2, tau, and apoE isoforms, either individually or in
combination, have been particularly informative. These transgenic animals have
been shown to develop early AD-like pathology including Aβ deposits, tau
immunoreactivitity along with progressive impairments in memory and learning
(Reviewed by Yamada and Nabeshima, 2000; Ashe and Zahs, 2010; Jucker,
2010). Non-transgenic animal models involving acute injection or continuous
infusion of Aβ into the rodent brain also exist and have been shown to cause
brain dysfunction and learning and memory deficits (Reviewed by Yamada and
Nabeshima, 2000).
In our lab a non-transgenic rat model of acute icv administration of Aβ25-35
has been developed and used as a model of AD. Aβ25-35 is the core neurotoxic
fragment of Aβ, retaining many of the same biological and physical properties of
the full-length peptide (Yankner et al., 1989; Pike et al., 1995; Millucci et al.,
2009).

Use

of

this

truncated

peptide

has

been

shown

to

induce

neuroinflammation, neuronal cell death, and synaptic loss similar to that seen
with Aβ1-40 and Aβ1-42 however, its smaller length allows for better solubility and
rapid aggregation into soluble oligomers (Kowall et al., 1992; Milluci et al., 2009).
Previous studies in our lab have demonstrated the initial effectiveness of this
non-transgenic rat model, with enhanced inflammatory responses, and Aβ
neurotoxicity being observed in the brains of 3 month old rats (Whitehead et al.,
2005a,b; Cheng et al., 2006; Whitehead et al., 2007). Other groups have also
demonstrated AD-like pathological changes in response to icv Aβ25-35
administration including glial activation, oxidative stress, hippocampal alterations
	
  21	
  

	
  

	
  

	
  

	
  

	
  

and memory impairments (Ruan et al., 2010; Zussy et al., 2011; Guo et al.,
2012). Zussy et al assessed the time-course and regional effects of single icv
injection of Aβ25-35 demonstrating the ability of Aβ25-35 to penetrate through the
ependymal cells lining the ventricles and reach the brain vasculature. The
injected peptide was found to locate in the septum, hypothalamus, hippocampus,
amygdala and various cortical regions and moreover was still present in the brain
3 weeks after injection (Zussy et al., 2011; Zussy et al., 2012).
1.13 Rationale:
Most studies examining the effect of icv injection of Aβ25-35 have done so
in 3 months old rats. However, AD is a disease of the elderly and apart from
genetic predisposition, aging is the most important risk factor for AD. With age
comes increased levels of ROS and decreased antioxidant functioning, amyloid
accumulation,

glial

activation,

increased

peroxisomal

and

mitochondrial

dysfunction and alterations in lipid and protein activity in the human brain. Each
of these age-related changes on their own are not sufficient to cause AD, but
together they render the brain vulnerable to further insult. Aβ toxicity is one such
insult thought to drastically alter many of the brain functions already affected by
the aging process. Therefore, this study investigated the age-related (3, 6 and 9
month) pathological response to icv administration of Aβ25-35. While the ages of 6
and 9 months are not considered particularly old for a rodent, they are more
physiologically relevant ages in terms of animal sexual, skeletal and social
maturity than are 3 months old animals (Quinn, 2005; Sengupta, 2011). Thus,
the first aim of this study was to determine whether the rodent brain is more
vulnerable to Aβ toxicity at 6 and 9 months than it was at 3 months, with
particular focus on neuroinflammatory and neurodegenerative changes.
A number of studies have shown that Aβ exerts its toxicity in part by
facilitating the formation of ROS, in particular H2O2, with a resultant increase in
oxidative damage. The aging process itself is also associated with an increase in
production of free radicals, along with a concurrent decrease in the ability to
defend against oxidative stress. One of the key enzymes responsible for
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maintaining oxidative balance in cells is catalase. Catalase is an antioxidant
enzyme, targeted to peroxisomes, that catalyzes the conversion of H2O2 to water
and oxygen. Aβ has been shown to inhibit catalase activity in cells, resulting in
increased H2O2 levels (Milton, 1999; Milton 2001; Habib et al., 2010). Moreover,
addition of catalase to Aβ challenged cells has been shown to protect cells from
Aβ toxicity by decreasing levels of H2O2 and reducing protein and lipid oxidation
(Behl et al., 1994; Manelli and Puttfarcken 1995; Sagara et al., 1996). A
genetically engineered variant of the enzyme, Catalase-SKL (CAT-SKL), with an
enhanced peroxisomal targeting signal that is able to enter tissues and cells and
traffic to peroxisomes has been developed. Use of CAT-SKL in vitro settings has
demonstrated the antioxidant, anti-inflammatory and anti-aging properties of this
recombinant enzyme (Koepke et al., 2007; Young et al., 2007; Price et al., 2009;
Undyala et al., 2011). Since Aβ and catalase-amyloid interactions result in
increased H2O2 levels, and addition of catalase to cell culture alleviates this
increase in H2O2, the use of catalase in vivo could be a targeted approach to
reducing the toxicity induced by Aβ. The second aim of this study was to treat
rats with CAT-SKL in an attempt to reduce the oxidative stress and
neuroinflammation induced by Aβ toxicity.
1.14 Hypothesis and Aims:
Aim 1: To investigate the age-related pathological response to Aβ25-35 toxicity
Hypothesis: Rats 6 and 9 months of age will demonstrate a greater pathological
response to Aβ25-35 toxicity than 3 months old rats, as evidenced by increased
neuroinflammation, cholinergic deficits, neuronal loss, and vascular impairment.
Aim 2: To evaluate whether the targeted antioxidant CAT-SKL is able to reduce
Aβ25-35 toxicity
Hypothesis: Catalase-SKL treatment will reduce the toxicity induced by Aβ25-35
administration in the mature rat brain by reducing oxidative stress and
inflammation, improving neuronal survival, and attenuating cognitive deficits.
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Section 2
METHODS
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2.1 Animals
All experimental procedures were carried out in accordance with the
guidelines of the Canadian Council on Animal Care and were approved by
Western University Animal Use Subcommittee. Male Wistar rats (Charles River,
Montreal Quebec) 3, 6 or 9 months of age were housed at a temperature of 2224°C under a 12h:12h light:dark cycle. Rats were provided food and water ad
libitum. Animals were randomly assigned to treatment groups and were housed
individually following surgery.
2.2 Aβ preparation
Aβ25-35 or the reverse peptide Aβ35-25 was purchased from Bachem and
dissolved in sterile saline at a concentration of either 4.24µg/µl or 21.2µg/µl and
then

stored

at

-80°C

in

30µl

aliquots.

Rats

received

bilateral

intracerebroventricular (icv) injections of either 100nmol or 500nmol of the toxic
Aβ25-35 (Bachem, Torrance California) or 100nmol or 500nmol of the reverse
peptide Aβ35-25. Acute administration of Aβ was as it has been shown by our lab
and others to induce progressive pathology in the rodent brain (Whitehead et al.,
2005ab; Cheng et al., 2006; Zussy et al., 2011; 2013). Aβ25-35 is the core
neurotoxic fragment of the full length Aβ1-42 peptide, retaining many of the same
physical and biological properties (Yankner et al., 1989). Aβ25-35 has been shown
to induce neurotoxic effects similar to that of the full-length peptide, while its short
length allows for better diffusion (Kaminsky and Kosenko, 2008). The reverse,
physiologically inactive, Aβ35-25 peptide was used as the control.
2.3 Surgery
Rats were weighed and then anesthetized in a Harvard anesthesia box
with 3% Isoflurane (Baxter Corporation, Mississauga Ontario) and oxygen. Once
anaethetized, rats were placed in a David Kopf stereotaxic apparatus, and were
maintained under gas anesthesia for the duration of the surgical procedure. The
hair on the surface of the rat’s head was shaved, and soap, ethanol and iodine
were used to clean and sterilize the surgery site. The skull was exposed and the
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ear and incisor bars were adjusted so that lambda and bregma were at the same
height, orienting the head in a flat-skull position. Bregma was then marked in
order to map out the injection sites. Injections sites were identified based on the
following coordinates with respect to bregma (Paxinos & Watson, 1986); -0.8mm
anterior/posterior, ±1.4mm medial/lateral, and -4mm dorsal/ventral (below dura).
Once located, small burr holes were made in the parietal bone to allow for
insertion of the injection cannula. Aβ25-35 or Aβ35-25 (details above) was injected
bilaterally into the lateral ventricles through a stainless steel cannula attached to
a glass Hamilton syringe at a rate of 1µl/30 seconds. The injection cannula was
left in situ for 5 minutes following each injection, and then removed slowly. The
surgery site was then sutured closed and rats were administered 0.3ml of the
analgesic Temgesic Buprenorphine hydrochloride subcutaneously and 0.03ml of
the antibiotic Baytril (Bayer) intramuscularly. Rats body temperature was
maintained at 37°C on a heating pad for the duration of the surgical procedure.
Following surgery rats were placed under a heat lamp until they could attain and
maintain sternal recumbency.
2.4 Treatment Groups
For the age-based part of the study animals 3, 6 and 9 months of age
were assigned randomly to the following treatment groups: low dose Aβ25-35
(100nmol in 25µl), high dose Aβ25-35 (500nmol in 25µl), or reverse peptide Aβ35-25
(RP) (100nmol in 25µl). Table 1 lists the number of animals in each of the
treatment groups that underwent successful surgeries and were used for further
analysis in the aged study. For the CAT-SKL study, six-month old rats received
bilateral intracerebroventricular injections of either Aβ25-35 (500nmol in 25ul) or
the reverse physiologically inactive Aβ35-25 peptide (500nmol in 25µl). Animals
were randomly assigned to one of four treatment groups: Aβ25-35 +CAT-SKL
(Aβ+CATSKL), reverse peptide Aβ35-25+ CAT-SKL (RP+CATSKL), Aβ25-35+saline
(Aβ) and reverse peptide Aβ35-25+saline (RP). The number of animals in each of
the treatment groups is outlined in Table 2.
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Table 1. Treatment groups and corresponding n values. Listed are the animals
that underwent successful surgeries and were included in the aged component of
the study.
3 Months

6 Months

9 Months

Reverse Peptide

n=6

n=6

n=6

Aβ 100nmol

n=6

n=7

n=6

Aβ 500nmol

n=6

n=6

n=6
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Table 2. Treatment Groups and Corresponding n values for behavior, and
immunohistochemical analysis for animals included in the CAT-SKL study.
Behavior

Immunohistochemistry

RP+ Saline

n=8

n=6

Aβ+ Saline

n=9

n=6

RP + CAT-SKL

n=9

n=7

Aβ + CAT-SKL

n=9

n=7
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2.5 Catalase Administration
Rats undergoing Catalase-SKL (CAT-SKL) treatment received a total of 4
catalase injections, once per week for 4 sequential weeks (Figure 2A). Animals
were weighed immediately prior to injection and were administered 1mg/kg of
CAT-SKL by intraperitoneal (ip) injection. Those animals not receiving CAT-SKL
injections received ip injections of an equivalent volume of saline. The dose and
route of CAT-SKL administration was based on unpublished work from
Dr.Terlecky’s lab. The recombinant enzyme CAT-SKL was acquired from Dr.
Paul Walton and Dr. Stanley Terlecky (United States patent 7601366 and related
patents pending). The molecule consists of a reengineered catalase enzyme,
with a SKL targeting sequence, along with a cellular delivery molecule (cell
penetrating peptide).
2.6 Behavior: Morris Water Maze
The Morris water maze (MWM) consisted of a circular pool (146cm in
diameter, 58cm high) in which rats were trained to escape from the water by
swimming to a hidden platform. The pool was filled (36cm high) with water and
was virtually divided into four equivalent quadrants: north-east (NE), north-west
(NW), south-east (SE) and south-west (SW). The water was made opaque using
non-toxic blue paint, and was maintained at a temperature of 21±1°C. A webcam
was placed above the pool to monitor the location and swimming activity of the
rats. The webcam was connected to a laptop for video recording and behavioral
parameters were measured using video-tracking software (ANY-maze®, Stoelting
CO, USA). Animals underwent four days of spatial learning, two probe trials (D12
and D19) and two days of cued learning (D20-D21) (Figure 2B).
Spatial Learning: Spatial learning took place from 8 to 11 (D8-D11) days after icv
injections of Aβ25-35 or Aβ35-25. The platform remained in the middle of the
southwest quadrant for the duration of the spatial acquisition trials. Distal extramaze cues were located around the room, with which rats could learn the
location of the hidden platform. The spatial acquisition phase consisted of 16
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Figure 2. Treatment paradigm and time course for CAT-SKL injections, Aβ
administration and behavior testing. (A) CAT-SKL or saline injections were
administered intraperitoneal once a week for four consecutive weeks. Aβ25-35 or
the reverse peptide Aβ35-25 was injected intracerebroventricularly (icv) on Day 0
and animals were sacrificed on Day 21. (B) Timeline for behavior testing in the
Morris Water Maze (MWM). Spatial learning took place from Day 8 to Day 11.
Rats underwent two probe trials, one on Day 12 and the second probe trial on
Day 19. Cued learning took place on Day 20 and Day 21.
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training trials, with 4 trials per day for 4 days with an inter-trial interval of 20
minutes. Rats were released from one of four start locations (N, SE, NW, E) in
randomized order and were allowed to swim in search of the platform for 90s. If
the rat was unable to locate the platform in that time, they were guided to the
platform and allowed to remain on it for 15s before being removed from the pool.
Animal behavior, including swimming speed, distance travelled and latency to
escape from the pool were monitored using video-tracking software (ANY-maze®,
Stoelting CO, USA).
Probe Trials: Twenty-four hours following the last spatial acquisition trial (D12),
rats were subjected to a probe trial where the platform was removed from the
pool. Rats were released from a NE start position and were allowed to swim
freely in the water for 30s. On the 19th day (D19) rats received an additional
probe trial for 30s to determine long-term memory retention. Rats were once
again released from the NE start position and were allowed to swim freely for
30s. For both the first (D12) and second (D19) probe trials the amount of time
and distance the rat travelled in the quadrant where the platform was previously
located was tracked and analyzed. Swimming speed, total path length and path
efficiency were also recorded. Time spent and/or distance travelled in the target
quadrant was taken as an index of rats’ memory capacity. Rats were not trained
during the time period between D12 and D19.
Cued Learning: On days 20-21 rats were trained in a non-spatial cued version of
the water maze. For cued training rats received 4 trails per day for 2 days, with
the location of the hidden platform and the rats start position varying with each
trial. The platform location was not predictable based on extra-maze cues, but
instead based on the presence of a cue attached to the platform. Swimming
speed, distance travelled and the latency to find the platform were recorded.
Cued platform learning was used as a control procedure in order to determine if
any differences in the MWM could be attributed to either a difference in
motivation to escape the water, or an inability to use cues to locate the hidden
platform.
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2.7 Sacrifice
Twenty-one days following surgery rats were weighed and then
euthanized with an overdose of Euthanyl (Pentobarbital Sodium, 240mg/mL)
(0.5mL-0.8mL, ip). Animals were perfused transaortically with 0.01M phosphatebuffer saline (PBS) (pH 7.35) for 2 minutes followed by 4% paraformaldehyde
(PFA) (pH 7.35) for 7 minutes. Brains were then removed and further fixed for 24
hours in PFA at 4°C after which they were transferred to a 30% sucrose solution
until they were ready for slicing. Brains were sliced into 35µm coronal sections
using a Leica CM1850 Cryostat (Leica Biosystems) and divided into 6 freefloating series. Series were stored in cryoprotectant (sucrose, ethylene glycol,
polyvinylpyrrolidone) at -20°C until they were needed for immunohistochemistry.
2.8 Immunohistochemistry
Day 1: Series representative of each treatment group were processed together to
reduce variability between groups. Free-floating coronal sections were washed in
0.1M PBS (6 X 10 minutes), and then incubated with 3% hydrogen peroxide for
10 minutes to block endogenous peroxidase activity. Sections were then washed
in 0.1M PBS (3 x 5 minutes), then blocked in 2% horse serum solution (1:200,
Vector Laboratories, Burlington, Canada) diluted in PBS with Triton-X (PBST) for
1 hour at room temperature. Sections were then incubated with primary
antibodies (Table 3) diluted in 2% horse serum (PBST) for 48 hours at 4°C on a
shaker. A mouse monoclonal antibody against Glial fibrillary acidic protein
(GFAP; 1:1000; Sigma-aldrich) was used to assess astrocyte activation. Ramified
microglia were detected using a mouse monoclonal antibody OX-6 directed
against the MHC II receptor (OX-6; 1:1000; Pharmingen). Monoclonal mouse
anti-choline acetyltransferase (ChAT; 1: 500; Abcam) was used to detect
cholinergic neurons (Table 3).
Day 2: Following incubation with the primary antibody, sections were briefly
washed in 0.1M PBS (3 x 5 minutes) and then incubated with biotinylated antimouse secondary antibody (1:2000, Vector Laboratories, Burlington, Canada) in
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2% horse serum solution for 1 hour at room temperature. Subsequently, sections
were washed in PBS (3 x 5 minutes) and incubated for 1 hour at room
temperature

with

Avidin-Biotinylated

Complex

(ABC)

Reagent

(Vector

Laboratories, Burlington, Canada) for 1 hour. Sections were washed once again
in PBS (3 x 5 minutes) and then visualized using 0.05% 3, 3’ diaminobenzidine
tetrahydrochloride (DAB) (Sigma-aldrich). Sections were incubated with DAB for
1-5min and then washed (0.1M PBS; 3x 5minutes) and mounted onto VWR
microscope slides in 0.3% gelatin. Slides were left to air dry, and were then
dehydrated in a graded series of ethanol (50%, 70%, 95%, 100%; 5 minutes
each) followed by Xylene for 10minutes, after which they were coversliped using
Depex Mounting medium.
2.9 Dual label immunohistochemistry
The same immunohistochemical procedure as described above was used for
dual label SMI71&Dysferlin staining with the following amendments:
Day 1: Following incubation with hydrogen peroxide, sections were incubated in
proteinase-K working solution for 10 minutes at 37°C. Sections were incubated
with primary antibody mouse monoclonal anti-dysferlin (1:200, Abcam) for 24
hours.
Day 2: Sections were washed in 0.175M sodium acetate (3x 5minutes) after
incubation with avidin-biotin peroxidase complex, and were then incubated with
Nickel-enhanced DAB, followed by washes in 0.175M sodium acetate (3
x5minutes). Sections then underwent a repeat of Day 1 staining as outlined
above followed by incubation with anti-SMI71 (1:2000, Covance) primary
antibody.
Day 3: Same as Day 2 staining outlined above for immunohistochemistry.
Immunohistochemical controls: As negative controls sections were incubated in
parallel but without the primary antibodies. A typical section showed no nonspecific binding (Figure 3).
	
  33	
  

	
  

	
  

	
  

	
  

	
  

Table 3. Overview of the primary antibodies used for immunohistochemistry.
Antibody

Host Species

Dilution

Target

Supplier

ChAT

Mouse
monoclonal

1:500

Cholinergic neurons

Abcam

Dysferlin

Mouse
monoclonal

1:200

Expressed by leaky
endothelial cells

Abcam

GFAP

Mouse
monoclonal

1:2000

Astrocytes

SigmaAldrich

OX-6

Mouse
monoclonal

1:1000

Microglia

Pharmingen

SMI71

Mouse
monoclonal

1:2000

Endothelial proteins
at Blood Brain
Barrier

Covance
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Figure

	
  

3.

Immunohistochemical

	
  

controls.

(A-D)

Representative

photomicrographs of the hippocampal CA1 and CA3 subfield, medial septal
nucleus/vertical diagonal band (MSN/VDB) and thalamus respectively in a 6
months old Aβ25-35 500nmol administered rat. Sections underwent the same
immunohistochemical staining protocol as described but without the primary
antibody. Scale bar 100µm.
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2.10 Histological Examination
Hematoxylin and Eosin (H&E) Staining: Free-floating sections were removed
from cryoprotection and washed in 0.1M PBS (6 x 10 minutes). Sections were
then mounted onto Superfrost microscope slides using 0.3% gelatin and air-dried
in preparation for staining. Sections were placed in Mayer’s Hematoxylin solution
for 4 minutes, rinsed under tap water for 5 minutes and then dipped in 0.05%
Eosin Y solution 9 times and rinsed in deionized water (ddH20). Sections were
then dehydrated in a graded series of ethanol (50%, 70%, 95%, 100%) followed
by 10 minutes in Xylene after which they were coverslipped using Depex
mounting medium. Representative sections from each treatment group were
processed simultaneously to reduce variability between groups.
Thionin Staining: Free-floating sections were removed from cryoprotection and
washed in 0.1M PBS (6 x 10 minutes). Sections were then mounted on
Superfrost micro slides using 0.3% gelatin and left to air dry. Sections were then
rehydrated in 100% ethanol (4min), 95% ethanol (4min), 70% ethanol (2min),
50% ethanol (2min) and ddH2O (1min) and then stained in 0.5% thionin for 20-25
seconds. Stained sections were then rinsed in ddH2O (2x10s) and dehydrated in
50% ethanol (2min), 70% ethanol (2min), 95% ethanol with 6 drops of acetic acid
(2.5min), 95% ethanol (5min) and 100% ethanol (5min). Finally, sections were
immersed in Xylene for 10 minutes and coverslipped using Depex mounting
medium.
2.11 Imaging & Quantification
Stained brain sections were photographed with a Leica DFC295 camera
coupled to a Leica DM IRE2 microscope (Leica Microsystems Inc., Concord,
Ontario, Canada) with Leica Application Suite Version 4.1.0 image analysis
software (Leica Microsystems). Analysis and quantification was carried out using
ImageJ 1.45s software (Wayne Rasband, National Institute of Health, Bethesda,
Maryland, USA).
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Regions of interest: Areas of the brain examined included the anterior cortex,
hippocampus, basal forebrain, thalamus, internal capsule, corpus callosum, and
the cerebral cortex. Further analysis and quantification was carried out
specifically in the medial septal nucleus (MSN) and vertical diagonal band (VDB)
of the basal forebrain (Bregma level 0.7mm to 0.2mm), the CA1 and CA3 regions
of the hippocampus (Bregma level -3.14mm to -3.8mm), and the posterior
thalamic, ventral posteromedial and ventral posterolateral thalamic nuclei
(Bregma level -3.14mm to -3.8mm) (Figure 4).
Microglia Cell counts: Images of OX-6 immunoreactive microglia in the
MSN/VDB, thalamus, and internal capsule were acquired at 10x magnification.
Images were taken from both the left and right side of the brain for the thalamus
and internal capsule. Two observers blinded to the treatment groups completed
cell counts from images by manually selecting positively stained microglia cells in
the predefined region of interest using ImageJ software. Four tissue sections per
rat corresponding to the brain region of interest were used for analysis.
Cholinergic neuronal counts: Images of ChAT positive neurons in the MSN/VDB
were acquired. Cholinergic neurons were counted by two observers blinded to
the treatment groups in five representative brain sections per rat within the same
5000µm2 area. Observers manually selected ChAT positive stained cells using
ImageJ software in the pre-identified MSN/VDB region of the basal forebrain.
Counts were then normalized to that of the control (Reverse Peptide) group
within an age group. Cholinergic neuronal numbers were then represented as the
% of cholinergic neurons in the MSN/VDB region relative to the control.
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Figure 4. Atlas representations of the rat brain. (A) The basal forebrain medial
septal nucleus (MSN) and vertical diagonal band (VDB). (B) The internal capsule
(IC), the posterior (Po), ventral posterolateral (VPL) and ventral posteromedial
(VPM) thalamic nuclei and the hippocampus (HC). Subregions of the
hippocampus including the CA1, CA2, CA3 and dentate gyrus (DG) are
represented in the bottom right part of the image.
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H&E cell counts: Photomicrographs of the left and right CA1 and CA3 region of
the hippocampus were taken at 20x magnification in H&E stained sections. The
total number of undamaged neurons within the same area were counted using
ImageJ software. Two different observers counted the number of undamaged
neurons in the CA1 and CA3 region of the hippocampus; the observers
completed the counts independently from one another and were blinded to the
experimental conditions. Only cells with a neuronal morphology were counted.
The number of undamaged neurons per optical field (neuronal density) was
determined in four tissue sections per rat.
Thionin cell counts: Images of the left and right CA1 and CA3 regions of the
hippocampus of thionin stained sections were acquired. Thionin staining was
completed to further evaluate neuronal integrity in the hippocampus. This method
gives the opportunity to assess cytoarchitecture as well as degenerative changes
in neurons in the regions of interest. The quantification measure, termed %
irregular neurons, was defined as the number of irregular neurons over the total
number of neurons counted in the region of interest. Damaged neurons were
recognized as cells that were severely misshapen and/or with changed nuclei
(pyknosis, karyorrhexis and karyolysis). Two different observers, independently
from each other and blinded to the experimental groups, completed cell counts of
both damaged and undamaged neurons in the CA1 and CA3 regions of the
hippocampus for all treatment groups.
Astrocyte Optical Density Measurements: Images of GFAP positive astrocytes
from both the left and right side of the CA1 and CA3 regions of the hippocampus
and in the thalamus were acquired at 20x magnification. Densitometric analysis
of GFAP immunohistochemistry staining was measured in 8-bit converted images
using ImageJ software in 4 tissue sections per rat. Optical density measurements
of GFAP staining were taken as correlates of astocytosis.
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2.12 Statistical Analysis
Statistical analysis was performed using GraphPad Prisim 4.0 for
Windows. Data was analyzed by performing a one-way or two-way analysis of
variance (ANOVA) followed by a Tukey’s or Bonferroni posttest respectively.
Data is expressed as mean ± S.E.M, and a p<0.05 was considered statistically
significant. In some cases statistical significance between treatment groups was
indicated using a lettering system on graphs. Letters shared in common between
or among groups indicated no significant differences.
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Section 3
RESULTS

	
  41	
  

	
  

	
  

	
  

	
  

	
  

	
  

3.1 Effects of Age and Aβ25-35 toxicity
3.1.1 Body Weight Changes
Rats were weighed on the day of Aβ25-35 or RP icv administration and once
weekly for the following 3 weeks. Changes in weight were calculated as weight
on day of sacrifice minus weight on day of surgery. No notable body weight
changes were identified between treatment groups for 3 month or 6 month rats.
Nine months old rats treated with 500nmol Aβ25-35 showed a significant loss in
body weight pre to post treatment in comparison to RP treated animals (p<0.05)
(Figure 5).
3.1.2 Neuroinflammation: Microglia Expression in the Medial Septal
Nucleus/Vertical Diagonal Band
Microglia are one of the key cellular mediators of inflammation in the brain,
and their activation and proliferation play critical roles in both acute and chronic
neuroinflammatory responses. In response to Aβ toxicity, microglia are activated
and have been shown to secrete a number of pro-inflammatory molecules. They
are also known to cluster around sites of Aβ deposition in the AD brain (Akiyama
et al., 2000). The basal forebrain cholinergic system appears particularly
susceptible to Aβ toxicity, and cholinergic neurons are one of the first neuronal
populations affected in the AD brain (Auld et al., 2002). Neuroinflammation, and
thus microglia recruitment and activation, has been shown to occur in vulnerable
regions of the AD brain. Thus, the basal forebrain, specifically the subdivision
that innervates the hippocampus, namely the medial septal nucleus (MSN) and
vertical diagonal bands (VDB), was examined in order to determine if this area
was susceptible to neuroinflammation in response to Aβ25-35 toxicity. Sections
were stained with the microglia marker OX-6 in order to examine microglia
reactivity, taken as a correlate of neuroinflammation.
Three months old Aβ25-35 500nmol rats had an increased number of
reactive microglia in the MSN/VDB compared to 3 months old RP animals
(p<0.05; Figure 6). There was a significant increase in microglia in the MSN/VDB
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Figure 5. Weight loss in 9 month Aβ25-35 treated rats. Changes in body weight
for 3, 6, and 9 month RP, Aβ25-35 100nmol and Aβ25-35 500nmol administered rats.
Change in weight was calculated as weight on day of perfusion minus weight on
day of reverse peptide Aβ35-25 or Aβ25-35 administration. Data is presented as
mean± SEM, *p<0.05 vs. the control RP (One-way ANOVA, Tukey’s post hoc).
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of 6 months Aβ25-35 500nmol treated rats in comparison to 6 month RP (p<0.001)
and Aβ25-35 100nmol (p<0.001) groups. Activated microglia were also significantly
higher in 9 month Aβ25-35 500nmol animals in comparison to 9 month RP (p<0.01)
and Aβ25-35 100nmol (p<0.001) animals. There was also an age-dependent
increase in activated microglia, with 6 month Aβ25-35 500nmol animals showing
significantly higher numbers of microglia in the MSN/VDB in comparison to 3
months Aβ25-35 500nmol animals (p<0.01; Figure 6). Therefore, higher doses of
Aβ25-35 toxicity resulted in increased activation of microglia in the MSN/VDB in 3,
6 and 9 month animals, and 6 and 9 month animals showed greater microglia
activation in the MSN/VDB in response to Aβ25-35 toxicity than 3 month animals.
3.1.3 Cholinergic neurons in the MSN/VDB
Degeneration of cholinergic neurons in the basal forebrain is a wellestablished hallmark of AD. The known vulnerability of this region to Aβ toxicity
combined with the increased microglia activation observed in the MSN/VDB of
the basal forebrain with age and Aβ25-35 toxicity, led to the evaluation of whether
cholinergic neuronal loss occurred in this region. Tissue sections containing the
MSN/VDB were stained using anti-choline acetyltransferase antibody (ChAT).
Choline

acetyltransferase

is

the

enzyme

responsible

for

synthesizing

acetylcholine and loss of ChAT staining indicates a loss of cholinergic neurons.
There were no significant differences in cholinergic neuronal number, shown as a
percentage of the control, between treatment groups in 3 months old rats (Figure
7G). At 6 months, the 500nmol Aβ25-35 group showed a significant decrease in
cholinergic neurons compared to both the 100nmol Aβ25-35 treated group (p<0.05)
and the RP group (p<0.05; Figure 7H). There was also a significant decrease in
number of cholinergic neurons in the MSN/VDB of 9 month 500nmol Aβ25-35
administered rats compared to the 9 month RP group (p<0.05; Figure 7I).
Therefore, it appears that high doses of Aβ25-35 in 6 and 9 months old rats
contribute to cholinergic neuronal loss. No differences in cholinergic neuronal
numbers in the MSN/VDB were seen within treatment groups between age
groups.
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Figure

	
  

6.

Increase

in

activated

	
  

microglia

in

the

Medial

Septal

Nucleus/Vertical Diagonal Band (MSN/VDB) in response to Aβ25-35. (A-F)
Representative photomicrographs of OX-6 immunopositive microglia in the
MSN/VDB of 3, 6 and 9 months old Aβ25-35 500nmol administered rats. Areas
boxed in lower power photomicrographs (20x) (A-C) are shown at higher power
(40x) in panels (D-F). Scale bar 100µm. (G) The number of OX-6immunoreactive microglia in the MSN/VDB of rats 3, 6 or 9 months of age
administered the control RP, Aβ25-35 100nmol or Aβ25-35 500nmol. Data are
presented as mean± SEM, means with different letters are significantly different
(Two-way ANOVA, Bonferroni posttest, p<0.05).
	
  45	
  

	
  

	
  

	
  

	
  

	
  

Figure 7. Age-dependent cholinergic neuronal loss in the basal forebrain.
(A-F) Representative images of ChAT immunolabeled cholinergic neurons in the
medial septal nucleus/vertical diagonal band (MSN/VDB) of the basal forebrain in
RP and Aβ25-35 500nmol administered animals 3, 6 and 9 months of age. Scale
bar 100µm (G-I) The percent change (relative to RP rats within an age group) of
ChAT positive neurons in MSN/VDB in RP, Aβ25-35 100nmol and Aβ25-35 500nmol
administered rats, 3, 6 or 9 months of age. Data presented as mean ±SEM,
*p<0.05 vs. RP group within an age-group (One-way ANOVA, Tukey’s posthoc).
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3.1.4 Neuroinflammation: Microglia and astroglial ractivity in the thalamus
Aβ deposition and neuroinflammation have been shown to occur in almost
all thalamic nuclei in both the human AD brain and in animal models of the
disease (Braak and Braak, 1990; Miao et al., 2005; Fan et al., 2007). Microglia
and astrocyte reactivity was examined in the thalamus in response to Aβ25-35
toxicity. Three months old rats showed little to no microglia activation in the
thalamus regardless of treatment. Microglia activation in the thalamus of 6
months old, 500nmol Aβ25-35 animals was significantly greater than 100nmol Aβ2535

(p<0.001) and RP (p<0.001) treated rats (Figure 8D). There were no significant

differences in microglia activation between treatment groups in the thalamus of 9month old rats. However, baseline levels of microglia in the thalamus of 9 months
old animals were elevated compared to that seen in 3 and 6 months old animals.
Both 6 and 9 months old rats exposed to 500nmol Aβ25-35 showed significantly
greater numbers of activated microglia in the thalamus compared to 3 month
Aβ25-35 500nmol animals (p<0.01 and p<0.05 respectively, Figure 8).
Glial activation in response to Aβ toxicity has been repeatedly reported
in cell culture and in animal models of AD (Akiyama et al., 2000). To determine if
there was an increase in activation or proliferation of astrocytes in response to
Aβ toxicity, GFAP immunohistochemistry was performed. GFAP is a marker of
astroglial reactivity. Optical density measurements of GFAP immunopositive
astrocytes revealed no statistically significant differences in astrocyte density in
the thalamus between ages or treatment groups (Figure 9).
3.1.5 Neuroinflammation: Astrocyte activation in the hippocampus
Qualitative analysis and quantitative optical density measurements of
GFAP immunolabeled astrocytes in the CA1 and CA3 regions of the
hippocampus were completed in order to examine whether Aβ25-35 toxicity
resulted in astrogliosis in these hippocampal regions. Qualtitative analysis
involved blinded assessements of the relative number of astrocytes in the
defined hippocampal subregions. Qualtitative assessments revealed an increase
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Figure 8. Age-related increase in thalamic microglia activation in response
to Aβ25-35. (A-C) Representative photomicrographs of OX-6 immunopositive
microglia in the thalamus of 3, 6 and 9 months old Aβ25-35 500nmol rats
respectively. Scale bar, 100µm. (D) The number of OX-6 immunoreactive
microglia cells in the thalamus (posterior thalamic, ventral posterolateral and
ventral posteromedial thalamic nuclei) of RP, Aβ25-35 100nmol and Aβ25-35
500nmol administered rats 3, 6 or 9 months of age. Data are presented as
mean± SEM, means with different letters are statistically different (Two-way
ANOVA, Bonferroni posttest, p<0.05).
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Figure 9. No changes in GFAP immunopositive astrocytes in the thalamus.
(A) Optical density measurements of GFAP immunoreactive astrocytes in the
thalamus of RP, Aβ25-35 100nmol and Aβ25-35 500nmol administered animals 3, 6
or 9 months of age. Optical density measurements are shown as a percentage of
the control RP group within an age group. Data are presented as mean ± SEM.
No statistically significant differences were seen between treatment groups within
an age group (Two-way ANOVA, Bonferroni posstest, p<0.05).
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in astrocyte density in the CA3 region of the hippocampus in 6 and 9 month
500nmol Aβ25-35 administered animals compared to RP administered animals
within an age group (Figure 10D,E, F). However, optical density measurements
of GFAP positive astrocytes in the CA3 region of the hippocampus only revealed
increased astrocyte density in 6 month Aβ25-35 500nmol animals compared to 6
month RP animals (p<0.05; Figure 10H). Three-month and 9-month old rats
showed no differences in astrocyte density in the CA3 region of the hippocampus
between treatment groups (Figure 10G,I). No differences in astrocyte density
were detected in the CA1 region of the hippocampus between age groups or
treatment groups (Data not shown).
3.1.6 Hippocampus integrity: H&E and thionin staining
Loss of hippocampal neurons occurs in normal aging and in AD, with the
CA1 and CA3 regions of the hippocampus being particularly susceptible to Aβ
toxicity (Gallagher and Nicolle, 1993; Landfield, 1988; Hayakawa et al., 2007).
Pyramidal neuronal numbers in the CA1 and CA3 region of the hippocampus
were measured from sections stained with H&E in rats 3 weeks after icv
injections of Aβ25-35 or the reverse Aβ35-25 peptide. Six months old animals
receiving 500nmol Aβ25-35 icv injections had a decrease in pyramidal cell counts
in the CA3 subfield of the hippocampus compared to 6 months old RP injected
rats (p<0.05; Figure 10E). In 9-month animals both 100nmol Aβ25-35 and 500nmol
Aβ25-35 icv injections resulted in a decrease in pyramidal cells in the CA3 region
compared to 9 month RP injected animals (p<0.01, p<0.001 respectively; Figure
11F). No differences in neuronal counts in the CA3 subfield between treatment
groups were identified in 3 months old rats (Figure 11D). Age and treatment had
no effect on number of pyramidal neurons in the CA1 hippocampal subfield
(Figure 11A-C).
To further evaluate neuronal integrity in the hippocampus and to
complement the H&E data, thionin staining was completed. This additional
histological stain was completed in order to assess neuronal morphology and
changes in neuronal numbers in response to Aβ25-35 toxicity. Total number of
	
  50	
  

	
  

	
  

	
  

	
  

	
  

Figure 10. Astrocyte activation in the CA3 region of the hippocampus. (A-F)
Representative photomicrographs of GFAP immunolabeled astrocytes in the CA3
subfield of the hippocampus in RP and Aβ25-35 500nmol administered rats 3, 6 or
9 months of age. Scale bar 100µm (G-I) Optical density measurements of GFAP
immunopositive astrocytes in the CA3 region of the hippocampus in 3, 6 or 9
month-old rats 21 days following icv administration of RP, Aβ25-35 100nmol or
Aβ25-35 500nmol. Optical density measurements are shown as a percentage of
the control, RP group within an age group. Data are presented as mean ± SEM,
*p<0.05 vs. RP group within an age-group (One-way ANOVA, Tukey’s post-hoc).
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Figure 11. Neuronal numbers in the CA1 and CA3 subfields of the
hippocampus. Variations in neuronal cell counts from Hematoxylin and Eosin
stained sections in the (A-C) CA1 and (D-F) CA3 hippocampal regions
determined 3 weeks after icv injection of RP, Aβ25-35 100nmol or Aβ25-35 500nmol
in 3, 6 or 9 month old rats. Pyramidal cell counts are shown as a percentage of
the control RP group within an age group. Data presented as mean ± SEM,
*p<0.05 vs. RP group within an age group (One-way ANOVA, Tukey’s post-hoc).
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neurons in the CA3 region of the hippocampus were determined, along with
number of neurons identified as being irregular, giving the reported measure of
percentage of irregular neurons. Irregular neurons were those identified as being
severely misshapen and/or with changed nuclei (pyknosis, karyorrhexis and
karyolysis). No differences in percentage of irregular neurons were identified
between treatment groups for 3 months old animals (Figure 12G). Six-month
Aβ25-35 500nmol administered animals had an increased number of irregular
neurons in the CA3 region of the hippocampus compared to 6 month RP animal
(p<0.01; Figure 12N). Animals 9 month of age receiving icv injections of Aβ25-35
500nmol also showed an increase in irregular neurons compared to 9 month RP
animals (p<0.05; Figure 12U).
3.1.7 Leakiness of cerebromicrovessels
Amyloid depositions in the vasculature, and disruption of the blood brain
barrier (BBB) have been implicated as playing a role in AD. To determine
whether age and Aβ25-35 toxicity play a role in the susceptibility of the brain to
vascular dysfunction dual-labeling for SMI71& Dysferlin was used to assess
leakiness of cerebromicrovessels. SMI71 staining is a marker for endothelial
proteins at the BBB and is localized to mature endothelial cells when the BBB is
intact (Sternberger and Sternberger, 1987). Staining for SMI71 is lost when there
is disruption of the BBB (Sternberger et al., 1989; Kim et al., 2012). Dysferlin
expression is associated with vascular leakage of serum proteins, indicative of
leaky blood vessels (Hochmeister et al., 2006). Qualtitative analysis involving
blinded assessment and ratings of extent of dysferlin staining and loss of SMI71
staining in defined regions was conducted.
Qualitative analysis of SMI71&Dysferlin staining showed an agedependent increase in BBB leakage in the thalamus, and hippocampus in
response to Aβ25-35 administration. Examination of cerebromicrovessels was
completed in the hippocampus of 3, 6 and 9 month RP, 100nmol Aβ25-35 and
500nmol Aβ25-35 icv injected animals. Three-month animals irregardless of

	
  53	
  

	
  

	
  

	
  

	
  

Figure 12. Thionin staining to evaluate neuronal integrity in the CA3 region
of the hippocampus. Representative photomicrographs of thionin stained cells
in the CA3 subfield of the hippocampus in RP, Aβ25-35 100nmol, and Aβ25-35
500nmol administered rats 3, 6 or 9 months of age. Areas boxed at lower power
(20x) are shown at higher power (40x) in the corresponding panel below.
Representative irregular neurons are indicated by arrows, scale bar 100µm.
(G,N,U) The number of irregular neurons shown as a percentage of total
neuronal counts in the hippocampal CA3 region for RP, Aβ25-35 100nmol and
Aβ25-35 500nmol administered rats 3, 6 and 9 months of age. Data are presented
as mean ± SEM, *p<0.05 vs. RP group within an age group (One-way ANOVA,
Tukey’s post hoc).
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treatment showed little to no dysferlin staining in the CA1 or CA3 subfields of the
hippocampus (Figure 13A,B,E,F). Animals 9 months of age showed minimal
dysferlin staining in the CA1 region of the hippocampus (Figure 13C,D). In the
CA3 hippocampal region 500nmol Aβ25-35 animals showed more dysferlin
staining than RP animals, with all 9 month treatment groups showing more
dysferlin staining than seen in the same regions in 3 months animals (Figure
13G-H).
The same thalamic nuclei imaged and analyzed for neuroinflammation
was evaluated for vascular integrity, namely the posterior thalamic, ventral
posteromedial and ventral posterolateral thalamic nuclei. At 3 months SMI71
staining was present throughout the thalamic region, and minimal dysferlin
staining was observed regardless of treatment (Figure 14A-B). Nine-month
animals showed dysferlin staining in the thalamic region in both RP and Aβ25-35
administered animals (Figure 14C-D). However, Aβ25-35 treated animals showed
greater amounts of dysferlin staining, with longer lengths of vessels being stained
for dysferlin. Animals six months of age showed an intermediate pathology
between that seen in 3 and 9-month old animals (Images not shown).
3.2 CAT-SKL and Aβ25-35 toxicity
In order to evaluate the potential of CAT-SKL treatment to reduce Aβ25-35 toxicity
similar analysis and quantification of the pathology as performed for the age and
Aβ25-35 toxicity study (Aim 1) was completed. All of these experiments were done
with 6 months old rats.
3.2.1 Body Weight Changes
Rats were weighed on the day of Aβ25-35 or RP Aβ35-25 icv administration
and once weekly for the following 3 weeks. Change in body weight was
determined based on weight on day 21 minus weight on day of icv Aβ25-35 or RP
administration. No significant changes in body weights were seen between
treatment groups. However, those animals in both Aβ and Aβ+CAT-SKL groups
lost more weight than those in the RP and RP+CAT-SKL groups (Figure 15).
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Figure 13. Cerebromicrovessels in the CA1 and CA3 subfields of the
hippocampus. Photomicrographs of SMI71& Dysferlin staining in (A-D) the CA1
and (E-H) CA3 regions of the hippocampus in 3 and 9 month old rats 3 weeks
after icv administration of RP, or Aβ25-35 500nmol. SMI71 (brown staining) is a
marker for endothelial proteins at the blood brain barrier and dysferlin (black/dark
brown staining), is a maker associated with vascular leakage of serum proteins.
Scale bar 100µm.
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Figure 14. Age-dependent leakiness of cerebromicrovessels in the
thalamus. Representative photomicrographs of SMI71 & Dysferlin staining in the
thalamus (posterior thalamic, ventral posteromedial and ventral posterolateral
thalamic nuclei) of 3 and 9 months old RP and Aβ25-35 500nmol administered
rats. Areas shown in lower power (10x) photomicrographs (A-D) are shown at
higher power (20x) in corresponding panels (E-H). SMI71 (brown staining) is a
marker for endothelial proteins at the blood brain barrier co-labeled with dysferlin
(black/dark brown staining), a maker associated with vascular leakage of serum
proteins. Scale bar 100µm.
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Figure 15. Body weight changes. Change in body weight in RP, RP+CAT-SKL,
Aβ and Aβ+CAT-SKL rats was calculated as weight on day of perfusion minus
weight on day of reverse peptide Aβ35-25 or Aβ25-35 icv administration.
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3.2.2 Neuroinflammation: Microglia expression in CAT-SKL treated animals
The significant activation of microglia in the MSN/VDB (Figure 6) and
thalamus (Figure 8) identified in 6 month Aβ25-35 injected rats lead to the
investigation of whether CAT-SKL treatment could diminish this microglia
response. The microglia marker OX-6 was used to evaluate microglia reactivity.
There was a significant increase in activated microglia in the MSN/VDB of Aβ25-35
icv injected rats when compared to the control RP (p<0.001), and RP+CAT-SKL
animals (p<0.001). Microglia activation in Aβ25-35 treated rats was effectively
reduced by treatment with CAT-SKL, with Aβ+CAT-SKL animals showing a
significant decrease in microglia in the MSN/VDB when compared to Aβ25-35
animals (p<0.05; Figure 16I).
Microglia activation in the thalamus was significantly greater in Aβ25-35
administered animals compared to the control RP group (p<0.05). CAT-SKL
treatment combined with Aβ25-35 administration reduced microglia activation in
the thalamus such that the microglia in the thalamus of Aβ+CAT-SKL animals
was not significantly different from both control groups (RP or RP+CAT-SKL)
(p>0.05; Figure 16J). However, this reduction in microglia was not significantly
lower than the Aβ25-35 treated animals.
3.2.3 Cholinergic neurons in the MSN/VDB in CAT-SKL treated animals
In accordance with the finding, described above, of decreased cholinergic
neuronal numbers in the MSN/VDB in older Aβ25-35 administered animals, the
number of ChAT positive neurons in the MSN/VDB was evaluated. Anti-choline
acetyltransferase antibody (ChAT) was used to stain cholinergic neurons in the
MSN/VDB. The number of ChAT positive cholinergic neurons in the MSN/VDB
was significantly reduced in Aβ25-35 administered animals compared to RP and
RP+CAT-SKL treated rats (p<0.05). With CAT-SKL treatment this significant
reduction induced by Aβ25-35 administration was lost and there were no significant
differences in cholinergic neuronal counts between Aβ+CAT-SKL treated rats vs.
RP and RP+CAT-SKL treated animals (p>0.05; Figure 17).
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Figure 16. CAT-SKL reduces microglia activation in the MSN/VDB and
thalamus. (A-D) Representative photomicrographs of microglia immunolabeled
with OX-6 in the medial septal nucleus/vertical diagonal band (MSN/VDB) and
(E-H) activated microglia in the thalamus of RP, RP+CATSKL, Aβ and
Aβ+CATSKL treated rats respectively. Scale bar 100µm. (I) The number of OX-6
immunopositive microglia in the MSN/VDB and (J) the number of OX-6
immunolabeled in the thalamus of RP, RP+CATSKL, Aβ and Aβ+CATSKL
treated rats. Data are presented as mean ±SEM, means with different letters are
significantly different (One-way ANOVA, Tukey’s post-hoc, p<0.05).
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Figure 17.

	
  

	
  

CAT-SKL prevents cholinergic loss in the MSN/VDB. The

number of ChAT positive cholinergic neurons shown as a percentage of the RP
group in the MSN/VDB of the basal forebrain in RP, RP+CAT-SKL, Aβ and
Aβ+CAT-SKL treated rats. Data are presented as mean ±S.E.M. Means with
different letters signify significance (One-way ANOVA, Tukey’s post-hoc, p<0.05).
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3.2.4 Astrocyte activation in the hippocampus of CAT-SKL treated animals
Optical density measurements of GFAP immunopositive astrocytes was
taken as a measurement of astroglial reactivity. Aβ25-35 administered animals
showed a significant increase in astrocyte density in the CA3 region of the
hippocampus compared to RP and RP+CAT-SKL treated animals (p<0.05 vs.
RP, p<0.01 vs. RP+CAT-SKL). CAT-SKL treatment reversed this increase in
astrocyte density induced by Aβ25-35 in the CA3 (p<0.05 Aβ vs. Aβ+CAT-SKL;
(Figure 18). No differences in astrocyte density were detected in the CA1 region
of the hippocampus between treatment groups (Data not shown).
3.2.5 Neuronal integrity in the hippocampus following Aβ25-35 administration
and CAT-SKL treatment
The known vulnerability of hippocampal neurons to Aβ25-35 toxicity lead to
the examination of neuronal integrity in the CA1 and CA3 subfields of the
hippocampus. The number of pyramidal neurons in the CA1 and CA3 region of
the hippocampus were determined using H&E and thionin staining 3 weeks after
icv injections of RP or Aβ25-35. Counts of H&E stained pyramidal neurons in the
CA1 region of the hippocampus revealed no differences in neuronal numbers
between treatment groups (Figure 19I). There was a significant reduction in
neuronal numbers in the CA3 region of the hippocampus in Aβ25-35 treated rats
compared to RP treated animals (p<0.05). With CAT-SKL treatment this
significant reduction in neuronal numbers was no longer observed. There were
no significant differences in pyramidal cell numbers between Aβ25-35 and
RP+CAT-SKL or Aβ+CAT-SKL treated rats (Figure 19J).
In order to further examine neuronal morphology and changes in neuronal
number in response to Aβ25-35 toxicity thionin staining was completed. The
number of neurons identified as being irregular over the total number of neurons
in the CA3 region of the hippocampus was determined, giving the reported
measure of percentage of irregular neurons. There was a significant increase in
percentage of irregular neurons in the CA3 region in Aβ25-35 administered animals
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Figure 18. CAT-SKL reduces astrocyte activation in the CA3 region of the
hippocampus. (A-D) Representative photomicrographs of GFAP immunolabeled
astrocytes in the CA3 region of the hippocampus of RP, RP+CAT-SKL, Aβ and
Aβ+CAT-SKL treated rats respectively. Scale bar 100µm. (E) Optical density
measurements of GFAP immunopositive astrocytes in the CA3 region of the
hippocampus shown as a percentage of the mean value of the RP group.
Different letters represent statistically significant differences (One-way ANOVA,
Tukey’s post-hoc, p<0.05).
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Figure 19. Neuronal integrity in the CA1 and CA3 regions of the
hippocampus. Representative photomicrographs of Hematoxylin and Eosin
stained cells in (A-D) the CA1 and (E-H) CA3 region of the hippocampus in RP,
RP+CAT-SKL, Aβ and Aβ+CAT-SKL treated rats respectively. Scale bar 100µm.
(I-J) Pyramidal cell numbers in the CA1 and CA3 subfields of the hippocampus
shown as a percentage of the control RP group. Different letters represent
statistically significant differences (One-way ANOVA, Tukey’s post hoc, p<0.05)
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compared to RP (p<0.01), RP+CAT-SKL (p<0.05) and Aβ+CAT-SKL (p<0.05)
administered animals. This increase in irregular neurons was prevented by CATSKL treatment. No differences in counts were seen between RP, RP+CATSKL,
or Aβ+CAT-SKL treated rats (Figure 20).
3.2.6 Behavior Testing: Morris Water Maze
To determine whether Aβ25-35 toxicity resulted in learning and memory
deficits and to also examine if CAT-SKL treatment was able to alleviate memory
or learning impairments animals were trained on a spatial learning task in the
Morris water maze (MWM), followed by two probe trials. The spatial task was
used to assess learning and the probe trials were used to assess reference
memory. Reference memory was determined based on animals’ preference for
the platform area when the platform was absent. Probe trial 1 took place on day
12 (D12), to assess short-term reference memory retention and probe trial 2 was
completed on day 19 (D19) to assess long-term reference memory retention.
Latency, path length and swimming speed during spatial learning
Rats were trained in the MWM 8 days after icv administration of Aβ25-35 or
RP. Rats were subject to a total of 16 spatial learning trials over a period of 4
days, with 4 trials per day. During the training days, latency (s) to reach the
platform, distance traveled (m) to reach the platform and average swimming
speed (m/s) were measured and analyzed. Latency and distance travelled to find
the platform decreased significantly over the course of acquisition training for all
treatment groups (p<0.001 Day 4 vs. Day 1), indicative of successful learning of
the task. There were no differences in latency or distance travelled to find the
platform between treatment groups, suggesting Aβ25-35 toxicity did not impair
spatial learning (Figure 21A-B). Average swimming speed appeared to decrease
over the training period for all groups, however this was not significant except for
the RP+CAT-SKL group who showed a significant reduction in mean swimming
speed over the course of the spatial learning trials (p<0.05 Day 1 vs. Day 4).
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Figure

	
  

20.

Thionin

staining

in

	
  

the

hippocampus.

Representative

photomicrographs of thionin stained cells in the CA3 subfield of the hippocampus
in RP, RP+CAT-SKL, Aβ and Aβ+CAT-SKL treatment groups. Areas boxed at
lower power (20x) (A-D) are shown at higher power (40x) in the panel below (EH). Representative irregular neurons are indicated by arrows, scale bar 100µm.
(I) The number of irregular neurons shown as a percentage of total neuronal
counts in the hippocampal CA3 region. Data are presented as mean ± SEM,
means with different letters are significantly different (One-way ANOVA, Tukey’s
post hoc, p<0.05).
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There were no differences in mean swimming speed between treatment groups
across training days (Figure 21C).
Probe Trial 1 on Day 12 (D12): Short-term memory retention
On day 12, 24 hours following the last spatial learning trial, rats were
subject to their first probe trial. The percentage of time spent and the percentage
of distance travelled in the target zone and average of the adjacent zones was
determined for the probe trial. The time spent and distance travelled in the target
quadrant was taken as an index of rats’ memory capacity. All treatment groups
spent significantly more time in the target zone than in the adjacent zones during
the D12 probe trial (p<0.05 for RP and RP+CAT-SKL, p<0.001 for Aβ and p<0.01
for Aβ+CAT-SKL; Figure 22A). RP+CATSKL, Aβ and Aβ+CAT-SKL also travelled
a significantly greater distance in the target zone than in the adjacent zones
(p<0.05, p<0.01, p<0.01 respectively; Figure 22B). The greater time spent and
distance travelled in the target zone over the adjacent zones indicates rats
remembered the platform location and sought it out during the D12 probe trial.
No differences in percentage of time spent or distance travelled in the target
zone was identified between treatment groups (Figure 22A-B).
Probe Trial 2 on Day 19 (D19): Long-term memory retention
On day 19, 7 days after the first probe trial, rats were subjected to a
second probe trial to assess long-term reference memory retention. As was done
for the first probe trial the percentage of time spent and the percentage of
distance travelled in the target zone and average of the adjacent zones was
measured and analyzed. There were no significant differences in percentage of
time spent in the target zone versus the adjacent zones across treatment groups.
However, RP+CAT-SKL, and Aβ+CAT-SKL treated animals all spent a
significantly greater percentage of time in the target zone than Aβ administered
animals (p<0.01 for RP+CAT-SKL vs. Aβ, p<0.05 for Aβ+CAT-SKL vs Aβ)
(Figure 22C). Animals from all treatment groups showed no significant
differences in distance travelled in the target zone compared to the adjacent
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Figure 21. Spatial learning during the hidden platform Morris Water Maze
(MWM) task. (A) Mean latency and (B) Path length to find the hidden platform in
the MWM during four consecutive days of training for RP, RP+CAT-SKL, Aβ and
Aβ+CAT-SKL treatment groups. Rats received 4 training trials per day with an
inter-trial interval of 20 minutes. Animals from all groups showed a reduction in
the mean latency and distance traveled to reach the hidden platform across
training days. (C) Average swimming speed for all treatment groups for each of
the training days during the spatial learning phase. No differences in mean speed
were seen between treatment groups (Two-way ANOVA, Bonferroni postest,
p<0.05).
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zones except for RP+CAT-SKL treated animals who travelled a greater distance
in the target zone than in adjacent zones (p<0.05; Figure 22D). RP, RP+CATSKL, and Aβ+CAT-SKL animals all travelled a greater distance in the target zone
than Aβ only animals (p<0.05 for RP vs. Aβ, p<0.001 for RP+CAT-SKL vs. Aβ,
p<0.01 for Aβ+CAT-SKL vs Aβ).
Comparison between probe trial on D12 and D19
The percentage of time spent and percentage of distance travelled in the
target zone on D12 (Probe 1) and D19 (Probe 2) were compared to determine if
there were any changes in reference memory across probe trials. Aβ
administered animals spent significantly less time and travelled significantly less
distance in the target zone on D19 compared to D12 (p<0.01). No significant
differences in time spent or distance travelled in the target quadrant between
D12 and D19 were found for RP, RP+CAT-SKL and Aβ+CAT-SKL treated rats
(p>0.05; Figure 23 A-B).

The reduction in time spent and distance traveled in

the target quadrant on D19 compared to D12 for Aβ25-35 animals indicates longterm reference memory deficits, which was effectively ameliorated in Aβ animals
treated with CAT-SKL.
Cued learning
On days 20-21 rats under went cued platform learning. Cued learning was
used as a control procedure in order to determine if any differences observed in
the MWM could be attributed to either a difference in motivation to escape the
water, or an inability to use cues to locate the hidden platform. A cue directly
attached to the platform was used to indicate the platforms position. Animals
were subjected to a total of 8 cued learning trials and data are presented as the
mean of the 8 trials. Animals across treatment groups showed no significant
differences in the time it took them to locate the platform, or distance travelled to
find the platform (Figure 24A-B). Average swimming speed was not significantly
different between treatment groups (Figure 24C). Thus, rats across treatment
groups demonstrated similar motivation and abilities to escape the water.
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Figure 22.

	
  

	
  

Probe trials: Short and long term memory retention. The

percentage of time spent and percentage of distance travelled in the target zone
and the average of the adjacent zones for RP, RP+CAT-SKL, Aβ and Aβ+CATSKL treated groups for (A-B) Probe trial 1, day 12 and (C-D) Probe trial 2, day
19. Means with different letters signify significance (Two-way ANOVA, Bonferroni
post-test, p<0.05).
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Figure 23. CAT-SKL reduces Aβ25-35 induced impairments in long-term
reference memory. (A) The percentage of total time spent and (B) percentage
of total distance traveled in the quadrant where the platform was located 24
hours following the last spatial learning trial (Probe 1) and 8 days after the last
spatial training trial (Probe 2) for RP, RP+CAT-SKL, Aβ and Aβ+CAT-SKL
treatment groups. Data are presented as mean ± S.E.M. Different letters indicate
significance (Two-way ANOVA, Bonferoni post hoc, p<0.05).
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Figure 24. Cued learning during the Morris Water Maze (MWM). (A) Mean
latency and (B) mean path length to find the cued platform in the MWM averaged
over 8 trials for RP, RP+CAT-SKL, Aβ and Aβ+CAT-SKL treated rats. No
differences in mean latency or distance traveled to reach the platform were seen
between treatment groups. (C) Average swimming speed for all treatment groups
over 8 cued learning trials. There were no differences in mean swimming speed
between treatment groups. Data are presented as the mean ± SEM of the 8 cued
learning trials (One-way ANOVA, Tukey’s post hoc, p<0.05).
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Section 4
DISCUSSION
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The results of this investigation in a rat model of amyloid toxicity revealed
two important findings. Firstly, the age of the animal plays a major role in the
development of pathological changes in response to Aβ25-35 toxicity. Secondly,
we have demonstrated for the first time that the targeted antioxidant CAT-SKL, a
genetically modified catalase molecule, is effective in preventing the pathological,
inflammatory and cognitive deficits induced by amyloid toxicity. In accordance
with previous findings this study showed that a single icv injection of Aβ25-35 in
male Wistar rats resulted in pathological changes in the brain 3 weeks after
injection (Whitehead et al., 2005ab; Cheng et al., 2006; Zussy et al., 2011; 2013).
Specifically, increased inflammation in the basal forebrain and thalamus,
cholinergic loss in the MSN/VDB and loss of neuronal integrity in the
hippocampus were shown. Moreover, this pathological response to Aβ25-35
toxicity was shown to be greater in 6 and 9 months old animals than in 3 months
old animals. This suggests that at the ages of 6 and 9 months, the rodent brain is
already more vulnerable to Aβ25-35 toxicity than it was at 3 months. Additionally,
this study was the first to use and demonstrate the beneficial effects of the
targeted antioxidant CAT-SKL in reducing Aβ25-35 toxicity in an animal model.
CAT-SKL

was

able

to

reduce

cholinergic

neuronal

loss,

decrease

neuroinflammation and attenuate long-term memory deficits induced by Aβ25-35
toxicity (Summarized in Figure 25).
4.1 Neuroinflammation
It has been well established that neuroinflammation plays a role in the
pathogenesis

of

AD,

and

that

Aβ

in

particular

contributes

to

the

neuroinflammatory response (Akiyama et al., 2000). The cellular mediators of
inflammation, microglia and astrocytes, were detected using OX-6 and GFAP
antibodies respectively, with increased microgliosis and astrocytosis being taken
as correlates of inflammation in the brain. Astrocyte activation in response to Aβ
toxicity has been repeatedly reported in cell culture and in animal models of AD
(Glass et al., 2010). This study showed an increase in astrocyte density in the
CA3 region of the hippocampus in Aβ25-35 administered 6 months old rats.
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However, no differences, using optical density measurements, in astrocyte
density were identified in the thalamus or CA1 subfield of the hippocampus in
rats regardless of treatment or age. The lack of differences seen in astrocyte
activation could in part be due to the inefficiency of optical density measurements
to detect changes in astrocyte reactivity. Astrocytes only occupy a portion of the
area from which optical density measurements were taken. Thus, even a large
increase in astrocytes would only result in a small change in optical density
measurements. Additionally, work by Zussy et al., reported increased GFAP
levels in the frontal cortex, amygdala and hypothalamus in response to Aβ
injection, however no changes in GFAP levels were identified in the
hippocampus (Zussy et al., 2013). Therefore, it may be that activation and
proliferation of astrocytes did not occur in the regions of the brain (thalamus,
hippocampus) examined in this study.
Six and 9 months old animals showed a significant increase in microglia
in the thalamus in response to Aβ25-35 administration compared to 3 months old
animals. The involvement of the thalamus in AD has not received the same
amount of attention as other brain structures. However, amyloid deposits and
neurofibrillary tangles have been shown to occur in almost all thalamic nuclei in
the human AD brain (Braak and Braak, 1990). Moreover, structural imaging
studies have shown reductions in thalamic volume in the brains of AD patients,
with thalamic atrophy correlating with impaired cognitive performance (de Jong et
al., 2008; Zarei et al., 2009). In animal models of the disease Aβ deposition,
neuroinflammation and neurodegeneration have been shown to occur in the
thalamus. Work by Miao et al., have shown in a transgenic mouse model of AD
that with increasing age there is extensive deposition of Aβ in the thalamic
microvasculature and that regions of the thalamus showing Aβ accumulation also
demonstrate enhanced levels of inflammatory cells (Miao et al., 2005; Fan et al.,
2007). Thus, the increased microglia activation in this region is in accordance
with the reported susceptibility of this region to AD pathology.
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Aβ-induced toxicity elicited an age and dose-dependent increase in
microglia in the MSN/VDB of the basal forebrain. Higher doses of Aβ25-35
administration resulted in a significant increase in microglia in the MSN/VDB in 3,
6 and 9 months old rats. Additionally, 6 and 9 months old rats had an increase in
microglia activation in this region when compared to 3 months old treatment
matched animals. This is in accordance with other studies in rodents that have
demonstrated administration of Aβ1-40 and Aβ25-35 results in increased levels of
reactive astrocytes and microglia in the basal forebrain (Scali et al., 1999,
Giovannini et al., 2002). The MSN and VDB are part of the basal forebrain
cholinergic system, which provides major cholinergic inputs to the hippocampus
and

neocortex

(D’Hooge

and

De

Deyn,

2001;

Auld

et

al.,

2002).

Neuroinflammation has been shown to occur in susceptible regions of the AD
brain, and basal forebrain cholinergic cells have been shown to be selectively
vulnerable to AD pathology (Auld et al., 2002). Furthermore, these Aβ-induced
inflammatory responses are thought to contribute to cholinergic hypofunction,
which is a well described change associated with human AD pathogenesis.
4.2 The basal forebrain cholinergic system
A significant decrease in the number of chAT immunolabeled cholinergic
neurons in the MSN/VDB of the basal forebrain was seen in Aβ25-35 500nmol
administered animals 6 and 9 months of age. This is in agreement with previous
studies that have demonstrated both single injection or prolonged exposure to Aβ
peptides, including Aβ1-40, Aβ1-42 and Aβ25-35, induces degeneration of cholinergic
neurons and results in memory impairment in rodents (Harkany et al., 1995;
Terranova et al., 1996; Vaucher et al., 2001; Colom et al., 2010;). Most of the
studies examining cholinergic loss in response to Aβ toxicity however, have
directly injected Aβ peptides into various basal forebrain structures including the
MSN and nucleus basalis of Meynert (Terranova et al., 1996; Colom et al., 2010).
This study was able to demonstrate cholinergic hypofunction in the MSN/VDB in
response to icv Aβ25-35 administration, better demonstrating the selective
vulnerability of this cholinergic neuronal population to Aβ toxicity, as amyloid was
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not directly injected into this region. Zussy et al., have shown similar results with
icv Aβ25-35 injections resulting in a decrease in cholinergic neurons in the basal
forebrain when examined at 3 weeks and 6 weeks post icv Aβ administration
(Zussy et al., 2011; 2013). Demonstrating a loss of cholinergic neurons in the
basal forebrain is of significance since it is believed to be one of the earliest
pathological events in AD and may contribute to the cognitive impairment
associated with the disease process (Auld et al., 2002).
The interplay between neuroinflammation and cholinergic neuronal loss in
the basal forebrain has not been extensively studied. However, the Aβ-induced
increase in microglia activation in this region accompanied by a decrease in
cholinergic neuronal numbers demonstrated in this study suggests inflammation
and cholinergic loss may be linked. The contribution of neuroinflammation to
cholinergic degeneration is supported by in vitro work that showed brain
inflammation, and in particular excessive microglia activation, selectively
damages cholinergic neurons in primary rat basal forebrain mixed neuronal/glial
cultures (McMillian et al., 1995). Additionally, infusion of lipopolysaccharide, a
potent inflammatory molecule, into the basal forebrain of young rats has been
shown to induce an extensive inflammatory response accompanied by a
significant loss of cholinergic neurons (Wenk et al., 2000). It is thought that
inflammatory processes that activate microglia and astrocytes results in the
release of cytokines and ROS, which in excess can be detrimental to cellular
functioning. Cholinergic neurons in the basal forebrain appear to be particularly
susceptible to the damaging effects of such molecules. Therefore, the increase in
microglia in the MSN/VDB in response to Aβ25-35 injection could be contributing to
cholinergic dysfunction in this region.
4.3 Neuronal integrity
Aβ25-35 induced toxicity was also associated with histopathological
changes in the hippocampus. The histological stains H&E and thionin revealed a
loss of pyramidal cells in the CA3 region of the hippocampus in Aβ25-35
administered 6 and 9-month-old animals. However, no changes in hippocampal
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cell numbers were identified in the CA1 hippocampal subfield. Similar results
have been demonstrated by other groups showing decreases in cell numbers in
the CA1, CA2 and CA3 regions of the hippocampus (Stepanichev et al., 2004;
Zussy et al., 2011; 2013). The loss of hippocampal cells as shown by histological
stains suggests impairments in neuronal integrity, however cell counts alone do
not confirm cell death. Work by others on the toxicity of the Aβ25-35 fragment
indicates that hippocampal cell loss is most likely the result of apoptotic
processes (Castro et al., 2010; Guo et al., 2013; Zussy et al., 2013). Cell death,
and more specifically apoptosis, could be more thoroughly analyzed using
alternative approaches including the labeling of apoptotic cells through dUTP
nick end-labeling (TUNEL), or through examination of caspase-3 and caspase-6
expression, both of which play a role in the execution phase of cell apoptosis.
Alternatively, necrosis could be examined. Evaluation of apoptosis and necrotic
cellular markers could confirm neurodegeneration in the regions examined, and
furthermore delineate the way in which cells are dying.
4.4 CAT-SKL
This study was the first to use the targeted antioxidant CAT-SKL to try to
reduce the toxicity induced by Aβ25-35 in the mature rat brain. CAT-SKL is a
genetically engineered derivative of the antioxidant enzyme catalase. The SKL
targeting sequence enables catalase to be more effectively targeted to
peroxisomes, where its main function is to metabolize H2O2 to oxygen and water.
Metabolism of H2O2 is critical, because it can react with Fe2+ to generate hydroxyl
radicals, which are highly reactive species capable of inducing protein, lipid and
DNA damage (Markesbery and Carney, 1999; Milton, 2004; Trippier et al., 2013).
Aβ25-35 toxicity was induced in 6 months old male Wistar rats. Animals 6 month of
age were used based on the findings from aim 1 of this study that demonstrated
significantly greater pathology and inflammation in 6 months old Aβ25-35
administered animals in comparison to 3 months old treatment matched animals.
In the present experiments, CAT-SKL was shown to reduce microglia
activation in the MSN/VDB and thalamus of 6 months old Aβ25-35 administered
	
  78	
  

	
  

	
  

	
  

	
  

	
  

rats. Reduction in microglia activation is likely a secondary consequence of the
anti-oxidant properties of the CAT-SKL molecule. By decreasing ROS production,
the toxicity induced by Aβ would be lessend therby decreasing the activation and
proliferation of inflammatory microglia and astrocytes. CAT-SKL may also have
aided in reducing the production of inflammatory molecules. Previous studies in
vitro have demonstrated the ability of CAT-SKL supplementation to reduce the
expression of the inflammatory cytokine TNF-α in a human cell model of
psoriasis (Young, 2008). Moreover, CAT-SKL has been shown to protect rat
myocytes from hypoxia-reoxygeneation and ischemia reperfusion injury via
reduction of oxidative stress in cell culture (Undyala et al., 2011).
The demonstrated ability of CAT-SKL to reduce oxidative stress and
inflammatory molecules is of particular relevance since Aβ is believed to exert its
toxicity in part by increasing ROS production. This has been demonstrated in
neuronal and astrocyte cell cultures where addition of Aβ results in increased
levels of ROS, and in particular H202 levels (Behl et al., 1994; Goodman et al.,
1994; Manelli and Puttfarcken, 1995; Harris et al., 1996). Moreover, in vivo
continuous infusion of Aβ1-40 has been shown to increase H2O2 formation, reduce
the activity of H2O2 degrading enzymes and increase the activity of H2O2
generating enzymes in the rat brain (Kaminsky and Kosenko, 2008). Thus, the
ability of CAT-SKL to specifically metabolize H2O2 may be of importance in
reducing Aβ mediated toxicity. Aβ is also known to upregulate the production of
inflammatory molecules, and activate microglia and astrocytes. Thus, CAT-SKL
may be exerting its beneficial effect by reducing Aβ-induced production of ROS
and inflammatory molecules, which in turn results in decreased microglia
activation and an overall reduction in the inflammatory response.
Treatment with CAT-SKL was also able to decrease cholinergic neuronal
loss in the MSN/VDB of the basal forebrain, and promoted neuronal survival in
the CA3 region of the hippocampus. Presumably this reduction in neuronal loss
is related to the decreased inflammation seen following CAT-SKL treatment. Aβ,
inflammation and ROS work in a self-propagating cycle, with the result being
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excessive neuroinflammation and oxidative damage that can disrupt normal
cellular functioning and ultimately lead to neuronal death. Stimulation of ROS
production and activation of inflammatory molecules in culture has been shown
to induce neuronal death. Moreover, Aβ has been shown to mediate cell death
via its production of ROS (Kadowaki et al., 2005).

Therefore, the protective

effect of CAT-SKL on neuronal functioning and survival could be via CAT-SKL
mediated reduction in ROS and inflammation.
Previous studies have investigated the role of catalase in maintaining
oxidative equilibrium. Addition of catalase to neuronal cultures challenged with
Aβ has been shown to reduce H2O2 levels and improve neuronal survival (Behl et
al., 1994; Manelli and Puttfracken, 1995; Zhang et al., 1996). Moreover, inhibition
of catalase activity has been shown to enhance the cytotoxicity of Aβ in neuronal
cultures (by increasing ROS levels), indicating an important role of this
antioxidant enzyme in maintaining oxidative balance (Behl et al., 1994; Milton,
2001). Work in a transgenic mouse model of AD has demonstrated the beneficial
effects of using a superoxide dismutase/catalase mimetic, EUK-207, to reduce
Aβ pathology. EUK-207 was shown to reduce oxidation of nucleic acids and lipid
peroxidation, and was able to decrease Aβ and tau accumulation (Clausen et al.,
2012). Moreover, the impact of ROS, and in particular H2O2 levels on longevity
has been examined in a transgenic mouse line overexpressing human catalase.
The study demonstrated a significant enhancement in murine lifespan in mice
overexpressing catalase when compared to wild type controls. This increased
longevity was attributed in part to the reduction in H202 levels and oxidative stress
(Schriner et al., 2005). Taken together these studies provide evidence for the
protective role of catalase in aging, and in reducing Aβ toxicity. The CAT-SKL
molecule may be of further benefit due to its unique targeting signal that directs it
to the organelle where it can carry out its function- the peroxisome. A model of
Aβ associated free radical oxidative stress, and the proposed interference of
CAT-SKL in the pathway are outlined in Figure 25.
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Figure 25. Summary of pathology induced by Aβ25-35 toxicity with and
without CAT-SKL treatment (A) Outline of pathology induced by Aβ25-35 icv
administration in rats (B) Pathology in rats administered Aβ25-35 and treated with
CAT-SKL. Boxes outlined in green were demonstrated in this study.
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4.5 Behavior Testing: Morris Water Maze
Spatial learning and reference memory was evaluated in rats using the
MWM (D’Hooge and De Deyn 2001;Vorhees and Williams, 2006). No differences
in performance were identified between RP, RP+CATSKL, Aβ and Aβ+CATSKL
treatment groups during the spatial learning task in the MWM, indicating animals
from all groups learned the task to the same degree. Other groups examining the
learning capabilities of rats in the MWM following icv injection of Aβ peptides,
including Aβ25-35, have shown deficits in spatial learning (Nabeshima and Nitta,
1994; Chen et al., 1996; Delobette et al., 1997; Guo et al., 2013). The
discrepancy between our finding and that of others could be attributed to
differences in the time at which behavior testing was started, and/or due to the
aggregation state of the Aβ peptide injected. Work by Delobette et al., showed
that the physical state of the peptide, whether aggregated or soluble, at the time
of injection influences animals performance in the spatial acquisition phase of the
MWM (Delobette et al., 1997). Moreover, a study examining the time course
based changes in response to Aβ25-35 toxicity showed that spatial acquisition in
rats starting behavioral testing one-week post Aβ25-35 injection did not
demonstrate spatial learning deficits. However, those animals beginning testing 2
or 3 weeks following Aβ25-35 administration showed spatial acquisition
impairments in the MWM (Zussy et al., 2011). Our study began spatial training 8
days after Aβ25-35 injection, and thus the short time frame may not have been
sufficient to allow for Aβ25-35 toxicity to impair spatial learning.
Reference memory was assessed during the probe trials, with probe trial 1
being used to evaluate short-term reference memory retention and probe trial 2
as an assessment of long-term reference memory (Patil et al., 2009). Animals
from all treatment groups successfully remembered the platform location during
the first probe trial, as indicated by their preference for the target zone over
adjacent zones. Additionally, no differences in performance between treatment
groups was identified, indicating at this time point Aβ25-35 toxicity did not result in
impairments in reference memory. During the second probe trial, 19 days after
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Aβ25-35 injection, animals showed a significantly decreased preference for the
target zone than animals from other treatment groups. Aβ25-35 injected animals
also spent less time and travelled a shorter distance in the target zone during the
second probe trial compared to the first probe trial. This decreased preference for
the target zone during the second probe trial was not seen in Aβ25-35
administered animals treated with CAT-SKL. Taken together this indicates that
Aβ25-35 icv administration induces long-term reference memory deficits, and
moreover treatment with CAT-SKL is able to attenuate Aβ25-35 induced long-term
reference memory impairments. These results confirm that cognitive impairment
develops approximately 3 weeks after the administration of amyloid peptides in
rats (Zussy et al., 2011).
During cued learning no differences in swimming speed, path length, or
latency to reach the cued platform location were identified between treatment
groups. Cued learning served as an important control procedure, as the task
requires many of the same basic abilities (intact eyesight, swimming ability) basic
strategies (learning to swim away from the wall, learning to climb on the platform)
and the same motivation (escape from the water) as the spatial version of the
task. If animals are not capable of performing the cued task it casts doubt on the
ability of animals to learn using distal cues in the spatial task (Vorhees and
Williams, 2006). Since animals from all treatment groups were found equally
competent at completing the cued task, differences in memory retention can
more reliably be attributed to differences in treatment.
The deficits seen in long-term reference memory could be a consequence
of cholinergic neuronal loss in the MSN/VDB of the basal forebrain induced by
Aβ25-35 toxicity. Moreover, the ability of CAT-SKL to reduce long-term reference
memory deficits in Aβ25-35 injected rats could be due in part to the ability of CATSKL to rescue cholinergic neurons. Previous studies have demonstrated that
lesions of the MSN and/or nucleus basalis of the basal forebrain impair MWM
performance in rodents (D’Hooge and De Deyn, 2001). Intracerebroventricular
injection of Aβ25-35 in mice has also been shown to induce MWM memory
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impairments that were reversed by the cholinergic agents tacrine and nicotine.
Tacrine is an acetylcholinesterase inhibitor, and nicotine is an acetylcholine
receptor agonist, both of which exert their effects by promoting cholinergic
functioning. The ability of tacrine and nicotine to reverse the behavioral deficits
induced by Aβ25-35 administration suggests that cholinergic dysfunction
contributes to spatial learning and reference memory impairments (Maurice et al.,
1996). The Aβ25-35 induced cholinergic deficits accompanied by impairments in
long term reference memory seem to be in accordance with the well-described
cholinergic dysfunction and memory impairments reported in AD.
4.6 Limitations and Future Directions
There are several limitations to this study, most of which are likely to be
resolved with further investigation. This study only examined the pathology
induced by Aβ-toxicity 21 days following icv administration. Evaluation of
pathology at additional time points would allow for a better understanding of the
time course of Aβ25-35 induced pathological changes in the brain and moreover
could help determine if Aβ-induced pathology is progressive in this model.
Additionally, this model only replicates some of the Aβ-induced pathological
changes associated with AD pathogenesis. AD is a complex disease and the
sequence of events causing it is not fully understood. Thus, no animal model is
able to fully simulate all aspects of the human AD condition. This does not
negate the usefulness of modeling aspects of the human disease in animals as
investigations in such models can help dissect out the complexity of the human
condition and provide useful information on the pathogenic impact and underlying
mechanisms

of

specific

components

of

the

disease

process.

Intracerebroventricular administration of Aβ25-35 in older animals provides an
adult-onset model of Aβ toxicity that demonstrates pathological changes
representative of the early stages of the disease process. Such a model is of
particular use when evaluating co-morbid conditions as has been done in our lab
in the past (Whitehead et al., 2005ab; 2007ab).
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This study was able to demonstrate the beneficial effect of CAT-SKL in
reducing Aβ25-35 toxicity in the rat brain, however numerous questions remain
unanswered and warrant further investigation in regards to the mechanism by
which CAT-SKL is reducing Aβ toxicity. Ongoing work in our lab is currently
investigating lipid peroxidation and DNA oxidation levels, both indicators of
oxidative stress, in the brains of rats treated with and without CAT-SKL. This
combined with more rigorous analysis of oxidative damage in the brain via the
use of biochemical assays will help elucidate whether CAT-SKL is exerting its
effect by reducing oxidative stress and increasing catalase levels in the rat brain.
Furthermore, since this was one of the first studies to use CAT-SKL in vivo and
information regarding the pharmacokinetics and pharmacodynamics of CAT-SKL
are limited, the optimal quantity and dosages of CAT-SKL are uncertain and
warrants further investigation. Finally, this was a proof-of principle study with
CAT-SKL administration beginning a week prior to Aβ25-35 icv injection; therefore,
the neuroprotective effects of CAT-SKL may be due to prevention rather than
treatment of Aβ25-35 toxicity. Future studies are needed to elucidate whether CATSKL would be beneficial in reducing pre-existing Aβ-induced pathology.
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Section 5
SUMMARY AND CONCLUSIONS
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This study demonstrated the importance of considering the age of the
animal when modeling Aβ toxicity. Intracerebroventricular administration of Aβ2535

in animals 6 and 9 months of age resulted in increased pathology compared to

Aβ25-35 induced pathology in 3 months old animals. Older animals showed
increased microglia activation in the thalamus and MSN/VDB, decreased number
of cholinergic neurons in the basal forebrain, and loss of neuronal integrity in the
hippocampus. The majority of studies investigating Aβ toxicity in non-transgenic
models of the disease administer Aβ in 2-3 month old animals. However, AD is a
disease of the elderly, with the most important non-genetic risk factor for lateonset AD being age. A number of changes occur in the brain with age, including
increased levels of ROS, increased production of inflammatory mediators,
reduced functioning of antioxidant enzymes, and accumulation of modified lipids
and proteins. While these changes alone may not manifest themselves as
impairments, the progressive accumulation of them over time may alter the brain
in such a way that renders it vulnerable to age-associated disease processes.
Interestingly, even at 6 and 9 months we were able to show increased Aβ
induced pathology, speaking to the important role that even these ages plays in
rendering the brain vulnerable to insult. Although 6 and 9 months is not
considered old for a rat, these ages provide a more physiologically relevant
equivalent to an adult brain than that of a 3 month animal (Quinn, 2005;
Sengupta, 2011). Therefore, icv administration of Aβ in animals 6 or 9 months of
age provides a model for adult-onset Aβ toxicity with pathological changes that
reflect the early stages of AD pathogenesis.
Using this adult-onset model of Aβ25-35 toxicity, we then investigated
whether the targeted antioxidant, CAT-SKL could reduce Aβ25-35 induced
pathology. Treatment with CAT-SKL decreased Aβ-induced microglia activation
and reduced cholinergic loss in the MSN/VDB of the basal forebrain. Moreover, it
decreased astrocyte activation and promoted neuronal survival in the CA3 region
of the hippocampus. CAT-SKL treatment also attenuated long-term reference
memory deficits induced by Aβ25-35 administration. The precise mechanism by
which CAT-SKL was able to reduce Aβ toxicity in vivo is unknown; however, the
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neuroprotective effects of the molecule are likely attributed to its antioxidant and
anti-inflammatory properties. This preclinical data provides support for the use of
CAT-SKL in reducing neuroinflammation and long-term reference memory
deficits induced by Aβ25-35.
Substantial

evidence

exists

implicating

oxidative

stress

and

neuroinflammation in the pathogenesis of AD. However, whether oxidative stress
is an initiator of AD pathogenesis or is a mediator of the disease process remains
to be answered. Nonetheless, oxidative stress appears to occur during the early
stages of the disease process, before the appearance of amyloid plaques and
neurofibrillary tangles in both humans and in animals models of the disease
(Dumont and Beal, 2011). Therapeutics aimed at restoring or maintaining the
homeostatic balance between production and elimination of ROS, and thus
reducing oxidative stress and inflammation during the early stages of the disease
may help in slowing disease progression and may aide in the protection of at-risk
individuals from the development of AD. The antioxidant molecule, CAT-SKL,
may therefore be a viable therapeutic approach for reducing oxidative stress and
neuroinflammation during the beginning stages of AD pathogenesis.
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